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Abstract 
Evaluation of patient demographics, clinical characteristics, and 
cardiovascular outcomes in patients with type 2 diabetes newly initiated 
on sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 
receptor agonists, and other antidiabetic medications 
Elmor David Pineda, M.S.P.S. 
The University of Texas at Austin, 2019 
Supervisor:  Karen L. Rascati
Co-Supervisor: James P. Wilson 
Objectives: To evaluate and compare patient characteristics and cardiovascular outcomes 
among adults with type 2 diabetes (T2D) newly initiated on sodium-glucose cotransporter-
2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and other 
antidiabetic medications (oADMs). 
Methods: This retrospective new user cohort study used administrative claims and 
electronic health record data from an integrated delivery network in Texas. Patients ages 
≥18 years with T2D and ≥1 prescription claim for either a SGLT-2i, GLP-1RA, or oADM 
filled between April 2013 through December 2018 were included. Patients were divided 
into three 1:1 propensity matched groups according to index medication identified. 
Pairwise comparisons of patient characteristics between SGLT-2is versus oADMs, GLP-
1RAs versus oADMs, and SGLT-2is versus GLP-1RAs were compared before and after 
matching. Primary outcomes were heart failure hospitalization and a composite endpoint 
 vii 
of myocardial infarction, stroke, unstable angina, or coronary. Secondary outcomes were 
the individual components of the composite endpoint. Cumulative incidences of all 
outcome variables were described using Kaplan-Meier failure plots and compared using 
log-rank tests and cox regression models. 
Results: Among 9,477 patients, 1,134 were SGL-2is initiators, 1,072 were GLP-1RA 
initiators, and 7,271 were oADM initiators. After propensity score matching, there were 
815 matched pairs for SGLT-2i versus oADM), 817 pairs for GLP-RA versus oADM, and 
947 pairs for SGLT-2i versus GLP-1RA. Patients initiating SGLT-2is versus oADMs had 
significantly lower risk of the composite endpoint (HR 0.69, 95% CI: 0.52-0.92), heart 
failure hospitalization (HR 0.66, 95% CI: 0.47-0.93), and unstable angina requiring 
hospitalization (HR 0.58, 95% CI: 0.41-0.82). Patients initiating SGLT-2is compared to 
oADMs had significantly lower risk of the composite endpoint (HR 0.70, 95% CI: 0.52-
0.94) and unstable angina requiring hospitalization (HR 0.59, 95% CI: 0.42-0.83). There 
were no differences in CV outcomes between SGLT-2is and GLP-1RAs. 
Conclusions: Both SGLT-2is and GLP-1RAs showed significant reductions in the 
composite outcome and unstable angina requiring hospitalization versus oADMs. 
However, only SGLT-2is were associated with a lower risk for heart failure 
hospitalizations. Nevertheless, CV outcomes were similar between SGLT-2is and GLP-
1RAs when compared to each other. This study provides real-world evidence for patients, 
payers, and providers, to consider selection of novel antidiabetic agents with CV benefits, 
SGLT-2is and GLP-1RAs, over other agents regardless of CVD status. 
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Chapter 1: Introduction 
1.1 EPIDEMIOLOGY OF TYPE 2 DIABETES 
Type 2 Diabetes (T2D) is a complex metabolic disorder that is characterized by persistent 
hyperglycemia as a result of varying degrees of insulin resistance and impaired insulin secretion.1 
Rates of both prevalence and incidence have been steadily increasing, mainly due to increases in 
obesity, sedentary lifestyles, and an increasing minority population. The Centers for Disease 
Control and Prevention’s (CDC) 2017 National Diabetes Statistics Report estimates that a total of 
30.3 million adults ages 18 years or older in the United States (US), 9.4% of the population, have 
diabetes with an incidence rate of approximately 1.5 million new cases of diabetes each year.2 The 
Southern and Appalachian regions of the US tend to have the highest prevalence rates of diabetes 
compared to others. In Texas, the estimated age-adjusted prevalence among adults was 10.9% 
(about 2.3 million) where Wichita, Tarrant, Waller, Angelina, Nacogdoches, Bowie, Anderson, 
and Dallas are among the top counties with the highest rates of prevalence.3 While these estimates 
do not differentiate between Type 1 Diabetes (T1D), T2D, and other diabetes types, they are more 
representative of the T2D population since it accounts for a disproportionately greater contribution 
to the prevalence of diabetes, representing 90-95% of all diabetes cases.1,2  
An analysis conducted using data from the National Health Interview Survey from 2016 
found that 8.6% of the US population (21.0 million) had T2D, while 0.55% (1.3 million) had T1D 
and 0.31% (0.8 million) had other diabetes types.4 The age group with the highest prevalence is  
≥65 years (19.62%) followed by 45-64 (11.03%), 30-44 (3.29%), and 18-29 (0.66%), which shows 
an increase in prevalence with age. Although prevalence is similar for males and females, it varies 
between racial and ethnic groups where it is highest in non-Hispanic blacks (11.52%) followed by 
Hispanics (9.07%), Asians (6.89%), and non-Hispanic whites (7.99%).  
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1.2 PATHOPHYSIOLOGY OF TYPE 2 DIABETES 
Patients with T2D exhibit defects in normal glucose metabolism, including impaired 
insulin secretion, insulin resistance, excess glucagon secretion, and glucagon-like-peptide-1 (GLP-
1) deficiency and resistance.1 Normally, insulin and glucagon work together to maintain normal 
plasma glucose levels in both the fasting and postprandial state. Insulin is released from pancreatic 
β-cells to lower plasma glucose levels by promoting glucose uptake and storage, while pancreatic 
α-cells release glucagon to counteract insulin’s effects by stimulating gluconeogenesis and 
glycogenolysis. Defects in one or both mechanisms can lead to clinically significant dysregulation 
of plasma glucose levels. 
Pancreatic β-cells rely on feedback regulation from insulin-sensitive tissues, including 
skeletal muscle tissue, adipose tissue, and liver tissue, in order to regulate their insulin secretion. 
Similarly, insulin-sensitive tissues rely on feedback from β-cells in the form of insulin secretion 
to mediate their uptake of glucose, fatty acids, and amino acids. During the early stages of insulin 
resistance, β-cells have the ability to increase insulin secretion through compensatory 
hyperinsulinemia and maintain glucose levels within normal physiological range.1,5,6 However, β-
cells are only capable of increasing insulin output to a certain extent in order to compensate for 
worsening insulin resistance. Over time, the demand for insulin overcomes the supply, which 
results in elevations in plasma glucose.  This inability to meet insulin demand to overcome 
peripheral insulin resistance is further compounded by progressive β-cell dysfunction or impaired 
insulin secretion, ultimately, leading to persistent hyperglycemia. 
The incretin system also plays an important role in maintaining normal plasma glucose 
homeostasis.1 Incretin hormones, GLP-1 and glucagon-dependent insulinotropic polypeptide 
(GIP), are released from intestinal endocrine cells in the small intestinal mucosa to stimulate 
insulin secretion in response to a meal.1,7,8 Both GLP-1 and GIP are the two principal mediators of 
the incretin effect that is responsible for a substantial portion of the postprandial insulin secretory 
response. The incretin effect refers to the 73% higher difference in insulin release that is observed 
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in a patient without T2D after an oral glucose load compared to an equivalent intravenous load in 
the same subject. This incretin effect is reduced or absent in the presence of impaired glucose 
tolerance and T2D, suggesting its role in the pathogenesis in T2D. 
The insulinotropic effects of GLP-1 remain relatively preserved compared to those of GIP 
in T2D. Experiments assessing the dose-response relationship between GLP or GIP and insulin 
secretion in patients with T2D demonstrated that supratherapeutic infusions of GIP had little to no 
effect on insulin secretion in response to glucose infusions, whereas similar infusions of GLP-1 
had significant effects on insulin secretion and normalized  β-cell sensitivity and responsiveness 
to glucose.7–9 However in subsequent experiments, infusions resulting in normal physiological 
concentrations of GLP-1 or GIP failed to show similar responsiveness, suggesting diminished 
GLP-1 potency in T2D.7,9 
1.3 CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES 
Cardiovascular disease (CVD) is the most prevalent cause of morbidity and mortality in 
patients with T2D.10 Patients with T2D have a disproportionately two-four-fold higher risk for 
atherosclerotic disease and develop CVD approximately 15 years earlier than their nondiabetic 
counterparts.11,12 It is estimated that approximately 32.2% of all patients with T2D have CVD, and 
roughly two-thirds of deaths in this population are CVD related.10 A majority of this excess risk 
can be attributed to the high prevalence of additional underlying risk factors that are widely present 
in this population, which includes hypertension, dyslipidemia, obesity, sedentary lifestyle, chronic 
kidney disease (CKD), and smoking. Thus, the link between T2D and CVD is multi-factorial and 
control of blood glucose alone does not necessarily eliminate CV risk.10,12 Joint management of 
T2D and CVD is imperative in lowering risk of CV events, including myocardial infarction (MI), 
coronary heart disease, ischemic stroke, and heart failure. 
Multiple mechanisms exist that participate in driving an increased risk for atherosclerotic 
CVD (ASCVD) in T2D, creating the perfect environment for atherosclerosis to occur.10 It has been 
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estimated that for every 1% increase in hemoglobin A1c (HbA1c) there is a 12% to 16% increase 
in CV events.13 Hyperglycemia, insulin-resistance, and hyperinsulinemia,  promote an increase in 
inflammation, oxidative stress, and a reduction in nitric oxide bioavailability, leading to 
endothelial dysfunction and greater atherosclerotic plaque burden.14–16 Inflammation promotes 
atherosclerotic lesions and increases the risk for hypercoagulability due to elevated circulating 
tissue factor, procoagulant proteins, and increased concentrations of plasminogen activator 
inhibitor-1 antigens. Patients with T2D also have higher rates of hypertension, dyslipidemia, 
obesity, and impaired glucose tolerance, which contributes to the development and progression of 
atherosclerosis as well. In the setting of compensatory hyperinsulinemia, endothelial dysfunction 
is further increased due to an increase in vasoconstrictors.  In addition, atherosclerotic plaques tend 
to be more unstable in patients with T2D, which can lead to plaque rupture and thrombosis. 
1.4 ECONOMIC BURDEN 
According to an economic report released by the American Diabetes Association (ADA) 
in 2018, the estimated total costs of diagnosed diabetes in the US in 2017 was $327 billion, which 
includes $237 billion in direct medical costs and $90 billion in lost productivity.17 This represented 
a 26% increase in total costs from $245 billion in 2012 and is expected to increase due to growths 
in both prevalence and medical costs.17,18 The largest drivers of direct medical costs were higher 
utilization of prescription medications to treat comorbid conditions of diabetes ($71.2 billion; 
30%) and hospital inpatient care ($69.7 billion; 30%), followed by antidiabetic medications and 
diabetes supplies (34.6 billion; 15%) and physician office visits ($30.0 billion; 13%).17 In addition 
to its significant clinical burden in diabetes, CVD has been identified as one of the primary cost 
drivers for medical costs for diabetes comorbidities and accounts for a quarter to one-half of all 
direct costs for diabetes.17–19 Adults with CVD and diabetes incur an additional $3,400 to $9,700 
per patient per year in health care costs compared to adults with only diabetes.19 It was estimated 
 5 
 
that in 2017, $37.3 billion in cardiovascular-related spending was associated with diabetes in the 
US alone.17 
1.5 CARDIOVASCULAR OUTCOME TRIALS 
In 2008, the Food and Drug Administration (FDA) issued a Guidance for Industry stating 
that all new pharmacological treatments for T2D should rule out unacceptable cardiovascular risk 
consisting of at least a three-point major adverse cardiovascular event (3P-MACE) composite of 
CV death, nonfatal MI, and nonfatal stroke.20 The upper limit of the 95% confidence interval for 
the hazard ratio had to be <1.8 for pre-marketing studies and <1.3 for post-marketing studies. The 
FDA’s guidance on establishing CV safety for novel antidiabetic medications were a result of the 
high CVD prevalence and burden in the T2D population coupled with the potential harm in 
increased CV risk that was found to be associated with traditional diabetes medications, such as 
the thiazolidinedione (TZD), rosiglitazone,21 and the dual peroxisome proliferator-activated 
receptor-α and -γ agonist, muraglitazar.22 These safety trials were meant to be designed as 
noninferiority trials to demonstrate that new antidiabetic agents are not associated with more major 
adverse cardiovascular events (MACE) compared to placebo; however, some of these trials were 
also powered to assess superiority as well to establish CV benefit. Prior to the FDA’s guidance 
statement, antidiabetic agents were largely evaluated upon their ability to lower glucose levels with 
the idea that improving glycemic control would benefit microvascular outcomes (retinopathy, 
neuropathy, and nephropathy). However, there was less certainty regarding whether there were 
CV benefits with intensive glycemic control due to negative findings from landmark trials, 
UKPDS, ACCORD, ADVANCE, and VADT, which showed no significant reductions in 
macrovascular outcomes.23–26 
As a result of several cardiovascular outcome trials (CVOTs) following the FDA Guidance 
statement, antidiabetic medications within two therapeutic drug classes, glucagon-like peptide-1 
receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT-2is) 
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provided positive results showing significant reductions in the risk of CV events in T2D patients, 
suggesting their cardioprotective effects. Currently, only three antidiabetic drugs have received 
FDA-approved labeling for CV risk reduction in patients with T2D and established CVD. 
Empagliflozin was the first antidiabetic agent to receive FDA-approval for CV risk reduction in 
2016, specifically to reduce the risk of CV mortality in adults with T2D and established CVD.  
Then in 2017, liraglutide became the first antidiabetic agent to receive FDA-approved labeling to 
reduce the risk of MACE (CV death, nonfatal MI, and nonfatal stroke) in adults with T2D and 
established CVD. Canagliflozin is the latest antidiabetic agent to receive approval for MACE risk 
reduction, which it gained in 2018. Most recently, the manufacturer of semaglutide filed for FDA-
approval for the same indication in March 2019. 
1.6 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS 
GLP-1RAs are a class of antidiabetic medications that are indicated for the treatment of 
T2D. They work to lower plasma glucose concentrations through multiple mechanisms by 
mimicking endogenous GLP-1 activity through activation of their receptors. This results in 
increased glucose-dependent insulin secretion, decreased inappropriate glucagon secretion, 
increased β-cell growth/replication, slowed gastric emptying, and decreased food intake. There are 
currently five out of six FDA-approved GLP-1RAs on the market: dulaglutide, exenatide, 
liraglutide, lixisenatide, and semaglutide. The sixth, albiglutide, was removed from the market by 
its manufacturers who announced their decision to discontinue the product in August 2017 and 
stated that it would no longer be available as of May 2018 due to a lack of utilization. 
The results of 5 CVOTs, ELIXA (lixisenatide),27 LEADER (liraglutide),28 SUSTAIN-6 
(semaglutide),29 EXSCEL (exenatide),30 and HARMONY OUTCOMES (albiglutide)31 have been 
published. The results from a sixth trial, REWIND (dulaglutide) have not yet been published; 
however, findings announced from an initial press release have shown significant reductions in 
3P-MACE compared to placebo.32 Results for each trial are summarized in Table 1.6.1. 
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Table 1.6.1 Summary of cardiovascular outcomes trials for glucagon-like peptide-1 receptor agonists 
 
  
ELIXA27 LEADER28 SUSTAIN-629 EXSCEL30 
HARMONY 
OUTCOMES31 
Author (year) Pfeffer et al. (2015) Marso et al. (2016) Marso et al. (2016) Holman et al. (2017) Hernandez et al. (2018) 
Sample Size (patients) 6,068 9,340 3,297 14,752 9,463 
Drug Lixisenatide vs. placebo Liraglutide vs. placebo Semaglutide vs. placebo 
Exenatide once weekly vs. 
placebo 
Albiglutide once weekly vs. 
placebo 
Main inclusion criteria 
T2D with acute coronary 
event within 180 days 
prior to screening 
T2D with pre-existing 
CVD, HF, or CKD ≥50 
years of age or 1 CV risk 
factor ≥60 years of age 
T2D with pre-existing 
CVD, HF, or CKD ≥50 
years of age or 1 CV risk 
factor ≥60 years of age 
T2D with or without pre-
existing CVD 
T2D with CVD ≥40 years 
of age 
HbA1c (%) 5.5-11.0 ≥7.0 ≥7.0 6.5-10.0 >7.0 
Mean Age (years) 60.3 64.3 64.6 62 64.1 
Median Follow-Up 
(years) 2.1 3.8 2.1 3.2 1.6 
Primary Outcome 4P-MACE* 3P-MACE† 3P-MACE† 3P-MACE† 3P-MACE† 
HR 1.02, CI (0.89-1.17) HR 0.87, CI (0.78-0.97) HR 0.74, (0.58-0.95) HR 0.91, CI (0.83-1.00) HR 0.78, CI (0.68-0.90) 
P=0.81 for superiority 
P<0.001 for noninferiority 
P=0.01 for superiority 
P<0.001 for noninferiority 
P=0.02 for superiority 
P<0.001 for noninferiority 
P=0.06 for superiority 
P<0.001 for noninferiority 
P=0.0006 for superiority 
P<0.0001 for noninferiority 
Secondary Outcomes           
Expanded MACE‡ HR 1.00, CI (0.90-1.11) HR 0.88, CI (0.81–0.96) HR 0.88, CI (0.62–0.89) - - 
4P-MACE* - - - - HR 0.78, CI (0.69–0.90) 
MI HR 1.03, CI (0.87–1.22) HR 0.86, CI (0.73–1.00) HR 0.74, CI (0.51–1.08) HR 0.97, CI (0.85–1.10) HR 0.75, CI (0.61–0.90) 
Stroke HR 1.12, CI (0.79–1.58) HR 0.86, CI (0.71–1.06) HR 0.61, CI (0.38–0.99) HR 0.85, CI (0.70–1.03) HR 0.86, CI (0.66–1.14) 
CV Death HR 0.98, CI (0.78–1.22) HR 0.78, CI (0.66–0.93) HR 0.98, CI (0.65–1.48) HR 0.88, CI (0.76–1.02) HR 0.93, CI (0.73–1.19) 
Unstable Angina HR 1.11, CI (0.47–2.62) HR 0.98, CI (0.76–1.26) HR 0.82, CI (0.47–1.44) HR 1.05, CI (0.94–1.18) - 
HF Hospitalization HR 0.96, CI (0.75–1.23) HR 0.87, CI (0.73–1.05) HR 1.11, CI (0.77–1.61) HR 0.94, CI (0.78–1.13) - 
* Composite endpoint including nonfatal MI, nonfatal stroke, and CV death, and unstable angina 
† Composite endpoint including nonfatal MI, nonfatal stroke, CV death 
‡ Composite endpoint including nonfatal MI, nonfatal stroke, CV death, unstable angina, and HF hospitalization 
HbA1c = Hemoglobin A1c; CI = 95% Confidence interval; CV = Cardiovascular; CVD = Cardiovascular disease; HF = Heart failure; HR = Hazard ratio; MACE = Major adverse 
cardiovascular events; MI = Myocardial infarction; T2D = Type 2 diabetes
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ELIXA, LEADER, SUSTAIN-6, and HARMONY OUTCOMES were carried out in patient 
populations with either established CVD or very high CV risk as well as T2D.27–29,31 On the other 
hand, EXSCEL was conducted in those with T2D regardless of the presence of prior CVD with 
73.1% having established CVD.30 All GLP-1RAs did not show an increase in CV events compared 
with placebo.27–29,31 Moreover, liraglutide, semaglutide, and albiglutide significantly decreased the 
risk of primary composite endpoint of cardiovascular events by 13%, 26%, and 22% (HR 0.87, 
95% CI: 0.78-0.97, HR 0.74, 95% CI: 0.58-0.95, and HR 0.78, 95% CI: 0.68-0.90) compared with 
placebo, respectively.28,29,31 In contrast, lixisenatide and exenatide did not show a statistically 
significant reduction in the risk.27,30 Thus, the results of the association between the use of GLP-
1RAs and CV risks may vary among the agents. However, the lack of significant CV risk reduction 
observed in ELIXA and EXSCEL may be related to multiple factors such as differences in the 
median follow-up time, the duration of exposure to the trial regimen, inclusion of patients with 
recent acute coronary syndrome who have a higher CV event risk, and the rate of discontinuation 
of the trial regimen due to adverse events. In addition, structural and pharmacokinetic differences 
may help to explain the varying clinical effects. However, specific reasons as to why the 
association between the use of GLP-1RAs and CV risks may vary among the agents, as well as the 
underlying mechanisms of the difference have not yet been explained. 
Several mechanisms have been proposed to explain the underlying CV benefits of GLP-
1RAs. The associated favorable weight loss to address obesity as a CV risk factor is due to their 
ability to decrease the rate of gastric emptying, thereby suppressing appetite. In addition to 
beneficial weight loss effects, they have been shown to reduce blood pressure, inflammation, 
ischemic injury, smooth muscle proliferation, and platelet aggregation, as well as increase 
vasodilation, blood flow, natriuresis, left ventricular function and heart rate, endothelial function, 
and plaque stability.33 Additionally, GLP-1RAs have demonstrated favorable effects on lipid levels 
by reducing total cholesterol, low-density lipoprotein, triglycerides, and apolipoprotein B. 
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1.7 SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS 
SGLT-2is are the latest class of antidiabetic agents to receive FDA approval that are 
indicated for the treatment of T2D. They exert their insulin-independent antihyperglycemic effects 
by inhibiting SGLT-2 in the proximal renal tubules of the nephrons, where roughly 90% of urinary 
glucose reabsorption occurs, to reduce reabsorption of filtered glucose from the tubular lumen and 
to lower the renal threshold for glucose, thereby increasing the urinary excretion of filtered 
glucose.34–36 There are currently four FDA approved SGLT-2is: canagliflozin, dapagliflozin, 
empagliflozin, and ertugliflozin. Canagliflozin, approved in April 1, 2013, was the first SGLT-2i 
marketed in the US.   
The results of 3 CVOTs, EMPA-REG OUTCOME (empagliflozin),37 CANVAS 
(canagliflozin),38 and DECLARE-TIMI 58 (dapagliflozin),39 have been published. A 4th trial, 




Table 1.7.1 Summary of cardiovascular outcome trials for sodium-glucose cotransporter-2 inhibitors 
  EMPA‐REG OUTCOME37 CANVAS38 DECLARE‐TIMI 5839 
Author (year) Zinman et al. (2015) Neal et al. (2017) Wiviott et al. (2018) 
Sample Size (patients) 7,020 10,142 17,160 
Drug Empagliflozin vs. placebo Canagliflozin vs. placebo Dapagliflozin vs. placebo 
Main inclusion criteria 
T2D with pre‐existing CVD with BMI ≤ 
45 kg/m2 and eGFR ≥ 30 mL/min/1.73 
m2 
T2D with pre‐existing CVD ≥30 years 
of age or ≥2 CV risk factors ≥50 years 
of age 
T2D with pre-existing CVD ≥40 years 
of age or CV risk factors ≥55 years of 
age (men) ≥60 years  of age (women) 
and CrCl ≥ 60 mL/min 
HbA1c (%) 7.0-10.0 7.0-10.5 ≥6.5-12.0 
Mean Age (years) 63.1 63.3 64.0 
Median Follow-Up (years) 3.1 2.4 4.2 
Primary Outcome 3P-MACE* 3P-MACE* 3P-MACE* 
HR 0.86, CI (0.74–0.99) HR 0.86, CI (0.75–0.97) HR 0.93, CI (0.84–1.03) 
P=0.04 for superiority 
P<0.001 for noninferiority 
P=0.02 for superiority 
P<0.001 for noninferiority 
P=0.17 for superiority 
P<0.001 for noninferiority 
    CV death or HF Hospitalization 
    HR 0.83, CI (0.73–0.95) 
    P=0.005 for superiority 
Secondary Outcomes       
4P-MACE* HR 0.89, CI (0.78–1.01) - - 
MI HR 0.87, CI (0.70–1.09)  HR 0.89, CI (0.73–1.09) HR 0.89, CI (0.77–1.01) 
Stroke HR 1.18, CI (0.89–1.56) HR 0.87, CI (0.69–1.09) HR 1.01, CI (0.84–1.21) 
CV Death HR 0.62, CI (0.49–0.77) HR 0.96, CI (0.77–1.18) HR 0.98, CI (0.82–1.17) 
Unstable Angina HR 0.99, CI (0.74–1.34)     
HF Hospitalization HR 0.65, CI (0.50–0.85) HR 0.67, CI (0.52–0.87) HR 0.73, CI (0.61–0.88) 
* Composite endpoint including nonfatal MI, nonfatal stroke, and CV death 
CI = 95% Confidence interval; CV = Cardiovascular; CVD = Cardiovascular disease; HbA1c = Hemoglobin A1c; HF = Heart failure; HR = Hazard ratio; MACE = Major adverse 
cardiovascular events; MI = Myocardial infarction; T2D = Type 2 diabetes
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Both EMPA-REG OUTCOME and CANVAS recruited patients with T2D and established CVD, 
whereas DECLARE-TIMI 58 also considered patients with high CV risk as well with 40.7% of 
the population having established ASCVD.  While empagliflozin and canagliflozin were found to 
both significantly reduce 3P-MACE by 14% (HR 0.86, 95% CI: 0.74–0.99 and HR 0.86, 95% CI: 
0.75–0.97, respectively) compared to placebo, dapagliflozin was only neutral in regards to 3P-
MACE. However, dapagliflozin was also powered for superiority to detect differences in the 
composite of heart failure hospitalizations and CV death and was found to significantly reduce the 
risk by 17% (HR 0.83, 95% CI: 0.73–0.95) compared to placebo.39 This was most likely driven by 
reductions in heart failure hospitalizations since assessment of secondary outcomes revealed a non-
significant reduction in CV death (HR 0.98, 95% CI: 0.82–1.17), but a significant reduction in 
hospitalizations for heart failure (HR 0.73, 95% CI: 0.61–0.88). These positive feart-failure related 
findings are consistent with empagliflozin and canagliflozin as well (HR 0.65, 95% CI: 0.50–0.85 
and HR 0.73, 95% CI: 0.61–0.88, respectively), which may be a signal that this may be a class 
effect; however, empagliflozin is the only SGLT-2i that showed significant reductions in CV death 
(HR 0.62, 95% CI: 0.49–0.77). Findings from CVOTs suggest that improvements in CV event risk 
may be more likely attributable to favorable hemodynamic changes rather than reductions in 
atherosclerotic burden, since improvements in heart failure hospitalizations occurred early in these 
trials. 
There are several proposed mechanisms to help explain the underlying CV benefits of 
SGLT-2is, independent of their glucose lowering properties. SGLT-2is have been shown to 
improve ventricular loading conditions through their diuretic and natriuretic effect, resulting in a 
reduction in preload.34 In addition, they have been shown to reduce blood pressure, arterial 
stiffness, and attenuate cardiac remodeling. They are also associated with improvements in cardiac 
metabolism and bioenergetics, thereby improving cardiac efficiency and output. This is thought to 
be mediated by a shift to a more efficient ketone-based cardiac metabolism to support bioenergetic 
homeostasis. Another proposed mechanism is their ability to decrease uric acid levels, which has 
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been associated with an increased risk in CV-related events; however, it is debated whether 
elevated uric acid levels is an independent predictor of CV risk.40 
1.8 TREATMENT GUIDELINES FOR TYPE 2 DIABETES 
While conventional goals of therapy are directed towards achieving optimal blood glucose 
levels, current recommended approaches to treatment requires continuous medical care utilizing 
multifactorial risk-reduction strategies that go beyond glycemic control. The primary goal in 
managing T2D is to reduce the risk of microvascular and macrovascular complications.41  
T2D management encompasses both lifestyle management and utilization of oral and 
injectable antihyperglycemic agents.42–44 The first step in the management of newly diagnosed 
T2D is to initiate lifestyle management, set an HbA1c target, and then initiate pharmacotherapy 
based on HbA1c at diagnosis. The ADA recommend an HbA1c goal of <7% for most patients with 
T2D with consideration for a more stringent goal of <6.5% or less stringent goal of <8% depending 
on patient specific factors, including hypoglycemia risk, duration of T2D, life expectancy, 
comorbid conditions, and/or complexity of pharmacotherapy. On the other hand, the American 
Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) 
support a HbA1c goal of ≤6.5% for most patients or a goal set >6.5% up to 8% if lower targets 
cannot be achieved without adverse events.44  
The ADA and AACE/ACE have published comprehensive treatment algorithms and 
guidelines for T2D management. For those with an initial HbA1c <9%, monotherapy may be 
considered, while those with an HbA1c >9% should consider dual therapy, and those with HbA1c 
>10%, high blood glucose (>300 mg/dl), or symptoms of hyperglycemia may consider 
combination injectable therapy. If HbA1c target is not achieved or maintained within 3 months, or 
at any point, lifestyle management should be reinforced and dual therapy considered. 
The emerging evidence of CV benefit of novel antihyperglycemic agents has created a 
paradigm shift in the management of T2D from focusing only on glycemic targets to focusing on 
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CV risk reduction. Consequently, both the ADA and AACE updated their algorithms to 
incorporate consideration of ASCVD at the point of dual therapy given the results of recently 
published CVOTs which suggests that certain antihyperglycemic drug classes, namely SGLT-2is 
and GLP-1RAs, may decrease the rate of CVD events and mortality through mechanisms in 
addition to their glycemic effects. In patients who do not have ASCVD, they recommend to 
consider a combination of metformin and any one of the preferred six treatment options: GLP-RA, 
SGLT-2i, dipeptidyl peptidase-4 inhibitor (DPP-4i), sulfonylurea, TZD, or basal insulin; the 
choice of which agent to add is based on drug specific effects and patient factors. However, for 
patients with ASCVD, they recommend adding a second agent with evidence of CV risk reduction 
after consideration of drug-specific and patient factors. At the time these guidelines were 
published, liraglutide, empagliflozin, and canagliflozin were the only drugs to receive FDA 
approved labeling to reduce CV risk in patients with T2D and established CVD. However, the 
manufacturers of semaglutide have recently submitted for FDA-approval of the same indication as 
well. 
In addition, CVD management in T2D encompasses use of anti-hypertensive agents, lipid-
lowering therapy, and anti-platelet therapy to decrease CVD risk in addition to glycemic control. 
Both the ADA and AACE both recommend a more comprehensive approach to T2D management 
to include managing CVD risk factors, such as hypertension and dyslipidemia. Others include 
smoking, family history of premature coronary disease, CKD, and the presence of albuminuria. 
1.9 STUDY RATIONALE 
The prevalence and economic burden of diabetes is steadily increasing with T2D 
representing 90-95% of all diabetes cases. CVD remains to be the most prevalent cause of 
morbidity and mortality in patients with T2D and is a primary cost driver for healthcare costs 
associated with diabetes management. While lifestyle modifications and metformin are still 
recommended as initial therapy, new guidelines have been updated by the ADA and AACE/ACE 
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incorporating recommendations on glucose-lowering medications with CV benefits, as well as 
emphasizing CV risk management. Antidiabetic agents within the SGLT-2i and GLP-1RA drug 
classes have demonstrated significant reductions in CV end points in CVOTs compared to placebo. 
However, it is uncertain whether these findings can be applied to the broader T2D population since 
these trials specifically included patients with established or high CV risk. 
To date, the real-world comparative potential reduction in CV outcomes associated with 
the use of SGLT-2is and GLP-1RAs compared to other antidiabetic medications (oADMs) as well 
as the comparative effects between the two classes in routine clinical practice remain uncertain. 
Although SGLT-2is and GLP-1RAs have shown positive benefits in CV outcomes, there have 
been no direct comparisons made between SGLT-2is versus GLP-1RAs. In a meta-analysis of 5 
GLP-1RA trials and 3 SGLT-2i trials that included 77,242 patients, 42,920 from GLP-1RA trials 
and 34,322 from SGLT-2i trials, comparing cardiovascular benefits of both drug classes in patients 
with and without ASCVD, both SGLT-2is and GLP-1RAs showed similar reductions in MACE 
11% (HR, 0.89, 95% CI 0.83-0.96; P=0.001) versus 12% (HR, 0.88, 95% CI 0.84-0.94; p<0.001), 
respectively.45 For patients with established ASCVD, both classes reduced MACE by 14% (HR, 
0.86, 95% CI, 0.80-0.93; P=0.002). For the individual MACE components, both SGLT-2i and 
GLP-1RA showed reduced MI by 11% (HR, 0.89; 95% CI, 0.80-0.98; p=0.02) and 9% (HR, 0.91; 
05% CI, 0.84-0.98; P=0.01), respectively. In addition, both significantly reduce cardiovascular 
death by 16% in SGLT-2is (HR, 0.84; 95% CI, 0.75-0.94; p=0.002) and 12% in GLP-1RAs (HR, 
0.84; 95% CI 0.75-0.94; P=0.002). However, significant reductions in stroke risk were only found 
in GLP-1RAs (HR, 0.86; 95% CI, 0.77-0.97; P=0.01) and not in SGLT-2is (HR, 0.97; 95% CI, 
0.86-1.10). Additionally, only SGLT-2is significantly reduced hospitalizations for heart failure 
(HHF) by 31% (HR, 0.69; 95% CI, 0.61-0.79; P<0.001) compared to a non-significant 7% 
reduction in GLP-1RA (HR, 0.93; 95% CI, 0.83-1.04; P=0.20). However, these results were 
limited to aggregated study-level data rather than patient-level data. Therefore, differences in 
patient characteristics could not be ascertained to explain variations in treatment effects. 
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There have been several retrospective studies that have examined CV outcomes associated 
with the use of these agents. In CVD-REAL, a large multi-national study that included 309,056 
patients across the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom, 
patients initiating SGLT-2is were compared to a propensity score matched sample of patients 
initiating other glucose-lowering agents in regards to heart failure hospitalizations and all-cause 
death.46 Results were pooled together to provide a weighted summary from all countries. Findings 
from their results showed a significant reduction in heart failure hospitalizations (HR 0.61, 95% 
CI: 0.51–0.73), all-cause death (HR 0.49, 95%CI: 0.41–0.57), and a composite of heart failure 
hospitalization or all-cause death (HR 0.54, 95% CI: 0.48–0.60) compared to other glucose-
lowering agents. However, they did not include other relevant CV-related outcomes, such as 
myocardial infarction, stroke, unstable angina requiring hospitalizations, or coronary 
revascularizations. In addition, they did not compare SGLT-2is to any specific class. Therefore, 
conclusions regarding the comparative CV outcomes between SGLT-2is and GLP-1RAs could not 
be ascertained. 
In CVD-REAL 2, a subsequent study of 235,064 patients across 6 countries in the Asia 
Pacific, the Middle East, and North American regions, initiators of SGLT-2is were compared with 
a propensity score matched sample of other glucose-lowering agents to also investigate risks for 
heart failure hospitalization and all-cause death, as well as myocardial infarction and stroke.47 They 
found that SGLT-2is were associated with a lower risk of all-cause death (HR 0.51, 95% CI: 0.37 
to 0.70), heart failure hospitalizations (HR 0.64, 95% CI: 0.50 to 0.82), a composite of all-cause 
death and heart failure hospitalizations (HR 0.60, 95% CI: 0.47 to 0.76), myocardial infarction 
(HR 0.81, 95% CI: 0.74 to 0.88), and stroke (HR 0.68, 95% CI: 0.55 to 0.84) compared to other 
glucose-lowering agents. While the investigators did improve in their methods by including 
myocardial infarction and stroke as CV endpoints, they still did not make any specific comparisons 
between SGLT-2is and specific drug classes. In addition, this study was limited to populations 
outside of the US. 
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In a similar study by Paterno et al., using a nationwide sample of commercially insured 
T2D patients, initiators of canagliflozin were compared to propensity score matched samples of 
GLP-1RA initiators. Their findings showed that canagliflozin was associated with lower risk of 
heart failure hospitalizations (HR 0.61, 95% CI: 0.47-0.78), no difference in risk of the composite 
CV endpoint (myocardial infarction and stroke) (1.03 (0.79-1.35), no difference in the risk of the 
expanded composite endpoint (primary composite CV endpoint, unstable angina, and coronary 
hospitalization), and no difference in the individual components of the composite endpoints. While 
this study did investigate the comparative effects of an SGLT-2i and GLP-1RA, they limited the 
study to a single agent without inclusion of other agents within the SGLT-2i class. 
As current interest has shifted from focusing solely on glycemic endpoints to incorporating 
CV outcomes of antihyperglycemic treatment to assess their effectiveness, real-world evidence 
comparing differences in CV outcomes between these two drug classes with demonstrated CV 
benefit and oADMs as the comparative CV outcomes between each other will be useful for well-
informed clinical decision making for patients, payers, and providers. 
1.10 STUDY OBJECTIVES AND HYPOTHESIS 
The aim of this study is to evaluate and compare patient demographics, clinical 
characteristics, medication utilization, and CV outcomes among adults with T2D who are newly 
initiated on SGLT-2is, GLP-1RAs, and oADMs. Specific objectives and null hypotheses of this 
study include: 
1. Describe and determine whether baseline demographics differ between T2D patients newly 
initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, and SGLT-2is versus 
GLP-1RAs. 
H01.1: The difference in age between patients newly initiated on SGLT-2is versus 
oADMs is not statistically significant. 
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H01.2: The difference in age between patients newly initiated on GLP-1RAs versus 
oADMs is not statistically significant. 
H01.3: The difference in age between patients newly initiated on SGLT2is versus 
GLP-1RAs is not statistically significant. 
H01.4: The difference in gender between patients newly initiated on SGLT-2is 
versus oADMs is not statistically significant. 
H01.5: The difference in gender between patients newly initiated on GLP-1RAs 
versus oADMs is not statistically significant. 
H01.6: The difference in gender between patients newly initiated on SGLT-2is 
versus GLP-1RAs is not statistically significant. 
H01.7: The difference in the proportion of patients of white race between patients 
newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H01.8: The difference in the proportion of patients of white race between patients 
newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H01.9: The difference in the proportion of patients of white race between patients 
newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
H01.10: The difference in the proportion of patients of other race between patients 
newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H01.11: The difference in the proportion of patients of other race between patients 
newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H01.12: The difference in the proportion of patients of other race between patients 
newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
H01.13: The difference in the proportion of patients of unknown race between 
patients newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H01.14: The difference in the proportion of patients of unknown race between 
patients newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
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H01.15: The difference in the proportion of patients of unknown race between 
patients newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
2. Describe and determine whether baseline prevalence of comorbidities differ between T2D 
patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, SGLT-
2is versus GLP-1RAs. 
H02.2: The difference in CCI scores between those who are newly initiated on GLP-
1RAs versus oADMs is not statistically significant. 
Ho2.3: The difference in CCI scores between those who are newly initiated on 
SGLT-2is versus GLP-1RAs is not statistically significant. 
H02.4: The difference in the proportion of patients with a history of CVD between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H12.5: The difference in the proportion of patients with a history of CVD between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.6: The difference in the proportion of patients with a history of CVD between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.7: The difference in the proportion of patients with a history of MI between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H12.8: The difference in the proportion of patients with a history of MI between 




H02.9: The difference in the proportion of patients with a history of MI between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.10: The difference in the proportion of patients with a history of stroke between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.11: The difference in the proportion of patients with a history of stroke between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.12: The difference in the proportion of patients with a history of stroke between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.13: The difference in the proportion of patients with a history of TIA between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.14: The difference in the proportion of patients with a history of TIA between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.15: The difference in the proportion of patients with a history of TIA between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.16: The difference in the proportion of patients with unstable angina between 




H02.17: The difference in the proportion of patients with unstable angina between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.18: The difference in the proportion of patients with unstable angina between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.19: The difference in the proportion of patients with angina pectoris between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.20: The difference in the proportion of patients with angina pectoris between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.21: The difference in the proportion of patients with angina pectoris between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.22: The difference in the proportion of patients with heart failure between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H02.23: The difference in the proportion of patients with heart failure between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H02.24: The difference in the proportion of patients with heart failure between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.25: The difference in the proportion of patients with PAD between those who 
are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H02.26: The difference in the proportion of patients with PAD between those who 
are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
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H02.27: The difference in the proportion of patients with PAD between those who 
are newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
H02.28: The difference in the proportion of patients with atrial fibrillation between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.29: The difference in the proportion of patients with atrial fibrillation between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.30: The difference in the proportion of patients with atrial fibrillation between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.31: The difference in the proportion of patients with hypertension between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.32: The difference in the proportion of patients with hypertension between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.33: The difference in the proportion of patients with hypertension between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.34: The difference in the proportion of patients with CKD between those who 
are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H02.35: The difference in the proportion of patients with CKD between those who 
are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H02.36: The difference in the proportion of patients with CKD between those who 
are newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
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H02.37: The difference in the proportion of patients with microvascular disease 
between those who are newly initiated on SGLT-2is versus oADMs is not 
statistically significant. 
H02.38: The difference in the proportion of patients with microvascular disease 
between those who are newly initiated on GLP-1RAs versus oADMs is not 
statistically significant. 
H02.39: The difference in the proportion of patients with microvascular disease 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is not 
statistically significant. 
H02.40: The difference in the proportion of patients with dyslipidemia between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H02.41: The difference in the proportion of patients with dyslipidemia between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H02.42: The difference in the proportion of patients with dyslipidemia between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H02.43: The difference in the proportion of patients with obesity between those who 
are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H02.44: The difference in the proportion of patients with obesity between those who 
are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H02.45: The difference in the proportion of patients with obesity between those who 
are newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
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3. Describe and determine whether baseline medication use differ between T2D patients 
newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, SGLT-2is versus 
GLP-1RAs. 
H03.1: The difference in the number of antidiabetic medications used between 
patients newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.2: The difference in the number of antidiabetic medications used between 
patients newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.3: The difference in the number of antidiabetic medications used between 
patients newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.4: The difference in the proportion of patients taking metformin between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.5: The difference in the proportion of patients taking metformin between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.6: The difference in the proportion of patients taking metformin between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.7: The difference in the proportion of patients taking DPP-4is between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.8: The difference in the proportion of patients taking DPP-4is between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.9: The difference in the proportion of patients taking DPP-4is between those 




H03.10: The difference in the proportion of patients taking sulfonylureas between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H03.11: The difference in the proportion of patients taking sulfonylureas between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.12: The difference in the proportion of patients taking sulfonylureas between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.13: The difference in the proportion of patients taking TZDs between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.14: The difference in the proportion of patients taking TZDs between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.15: The difference in the proportion of patients taking TZDs between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.16: The difference in the proportion of patients taking meglinitides between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H03.17: The difference in the proportion of patients taking meglinitides between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.18: The difference in the proportion of patients taking meglinitides between 




H03.19: The difference in the proportion of patients taking insulin between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.20: The difference in the proportion of patients taking insulin between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
Ho3.21: The difference in the proportion of patients taking insulin between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
Ho3.22: The difference in the proportion of patients taking ACEis, between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.23: The difference in the proportion of patients taking ACEis, between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.24: The difference in the proportion of patients taking ACEis, between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.25: The difference in the proportion of patients taking ARBs between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.26: The difference in the proportion of patients taking ARBs between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.27: The difference in the proportion of patients taking ARBs between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.28: The difference in the proportion of patients taking beta blockers between 




H03.29: The difference in the proportion of patients taking beta blockers between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.30: The difference in the proportion of patients taking beta blockers between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.31: The difference in the proportion of patients taking calcium channel 
blockers (CCBs) between those who are newly initiated on SGLT-2is versus 
oADMs is not statistically significant. 
H03.32: The difference in the proportion of patients taking CCBs between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.33: The difference in the proportion of patients taking CCBs between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.34: The difference in the proportion of patients taking thiazides between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.35: The difference in the proportion of patients taking thiazides between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.36: The difference in the proportion of patients taking thiazides between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.37: The difference in the proportion of patients taking loop diuretics between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H03.38: The difference in the proportion of patients taking loop diuretics between 
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those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.39: The difference in the proportion of patients taking loop diuretics between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.40: The difference in the proportion of patients taking nitrates between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.41: The difference in the proportion of patients taking nitrates between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.42: The difference in the proportion of patients taking nitrates between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.43: The difference in the proportion of patients taking anticoagulants between 
those who are newly initiated on SGLT-2is versus oADMs is not statistically 
significant. 
H03.44: The difference in the proportion of patients taking anticoagulants between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.45: The difference in the proportion of patients taking anticoagulants between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.46: The difference in the proportion of patients taking antiplatelets between 




H03.47: The difference in the proportion of patients taking antiplatelets between 
those who are newly initiated on GLP-1RAs versus oADMs is not statistically 
significant. 
H03.48: The difference in the proportion of patients taking antiplatelets between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
H03.49: The difference in the proportion of patients taking statins between those 
who are newly initiated on SGLT-2is versus oADMs is not statistically significant. 
H03.50: The difference in the proportion of patients taking statins between those 
who are newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H03.51: The difference in the proportion of patients taking statins between those 
who are newly initiated on SGLT-2is versus GLP-1RAs is not statistically 
significant. 
4. Describe and determine whether HbA1c prior to initiation of study medications differs 
between T2D patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus 
oADMs, SGLT-2is versus GLP-1RAs. 
H04.1: The difference in proportion of patients missing HbA0c values newly 
initiated on SGLT-2is versus oADMs is not statistically significant. 
H04.2: The difference in proportion of patients missing HbA1c values newly 
initiated on GLP-1RAs versus oADMs is not statistically significant. 
H04.3: The difference in proportion of patients missing HbA1c values newly 
initiated on SGLT-2is versus GLP-1RAs is statistically significant. 
H04.4: The difference in HbA1c between patients newly initiated on SGLT-2is 
versus oADMs is not statistically significant. 
H04.5: The difference in HbA1c between patients newly initiated on GLP-1RAs 
versus oADMs is not statistically significant. 
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H04.6: The difference in HbA1c between patients newly initiated SGLT-2is versus 
GLP-1RAs is not statistically significant. 
5. Determine whether the cumulative incidence or hazard of CV outcomes differ between 
T2D patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, 
SGLT-2is versus GLP-1RAs. 
H05.1: The difference in the cumulative incidence or hazard of the composite CV 
endpoint between patients newly initiated on SGLT-2is versus oADMs is not 
statistically significant. 
H05.2: The difference in the cumulative incidence or hazard of the composite CV 
endpoint between patients newly initiated on GLP-1RAs versus oADMs is not 
statistically significant. 
H05.3: The difference in the cumulative incidence or hazard of the composite CV 
endpoint between patients newly initiated on SGLT-2is versus GLP-1RAs is not 
statistically significant. 
H05.4 The difference in the cumulative incidence or hazard of hospitalizations for 
heart failure between patients newly initiated on SGLT-2is versus oADMs is not 
statistically significant. 
H05.5: The difference in the cumulative incidence or hazard of hospitalizations for 
heart failure between patients newly initiated on GLP-1RAs versus oADMs is not 
statistically significant. 
H05.6: The difference in the cumulative incidence or hazard of hospitalizations for 
heart failure between patients newly initiated on SGLT-2is versus GLP-1RAs is not 
statistically significant. 
H05.7: The difference in the cumulative incidence or hazard of MI between patients 
newly initiated on SGLT-2is versus oADMs is not statistically significant. 
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H05.8: The difference in the cumulative incidence or hazard of MI between patients 
newly initiated on GLP-1RAs versus oADMs is not statistically significant. 
H05.9: The difference in the cumulative incidence or hazard of MI between patients 
newly initiated on SGLT-2is versus GLP-1RAs is not statistically significant. 
H05.10: The difference in the cumulative incidence or hazard of unstable angina 
requiring hospitalization between patients newly initiated on SGLT-2is versus 
oADMs is not statistically significant. 
H05.11: The difference in the cumulative incidence or hazard of unstable angina 
requiring hospitalization between patients newly initiated on GLP-1RAs versus 
oADMs is not statistically significant. 
H05.12: The difference in the cumulative incidence or hazard of unstable angina 
requiring hospitalization between patients newly initiated on SGLT-2is versus 
GLP-1RAs is not statistically significant.
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Chapter 2: Methodology 
2.1 STUDY DESIGN 
This population-based study used a retrospective observational new user cohort study 
design to assess the effects of initiating SGLT-2is versus oADMs, GLP-1RAs versus oADMs, 
SGLT-2is versus GLP-1RAs on CV outcomes in patients with T2D. An active comparator, new 
user or incident user study design was selected over a prevalent user study design to eliminate the 
need to adjust for confounding due to pretreatment effects and overestimating medication benefits 
and/or safety.48 In addition, focusing on new users provided the ability to capture all outcome-
related events occurring after the initial start of therapy as well as reduced the potential for 
confounding bias by varying disease severity. 
2.2 DATA SOURCE 
This study utilized administrative claims and electronic health record (EHR) data from 
April 1, 2012 through December 31, 2018. Patient-level data were extracted from the Virtual Data 
Warehouse (VDW), which houses pharmacy and medical claims for the Scott and White Health 
Plan (SWHP), and EHR data from the Baylor Scott and White Health (BSWH) System. SWHP 
has approximately 415,000 covered lives, geographically located within the central and northern 
Texas regions and includes a payer mix of commercial, Medicare and Medicaid populations. 
BSWH is a non-profit, integrated delivery network, which includes a network of 48 acute care 
hospitals and more than 900 patient care sites with approximately 6,000 physicians and other 
healthcare providers. Unique member identification numbers were used to longitudinally link 
pharmacy and medical claims to patient enrollment and medical care data containing demographic 
information. Pharmacy claims provided details from all dispensed prescriptions, including drug 
name, National Drug Code (NDC), prescription filled date, quantity dispensed, days supplied, and 
prescriber information. Medical claims provided detailed information on inpatient and outpatient 
services, including encounter dates, place of service, procedure codes, and up to 5 International 
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Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) and International 
Classification of Diseases, Tenth Edition, Clinical Modification (ICD-10-CM) diagnosis codes per 
episode of care. This study was approved by the Baylor Scott & White Health and the University 
of Texas institutional review board following expedited review. 
2.3 SAMPLE SELECTION 
Patients were included if they were aged 18 years or older at the time of cohort entry, a 
diagnosis of T2D, at least 12 months of continuous health plan enrollment in the pre-index 
(baseline) period, and at least one prescription claim for either a SGLT-2i, GLP-1RA, or oADM 
(metformin, DPP-4is, sulfonylureas, TZDs, meglinitides, and insulin) filled between April 1, 2013 
through December 31, 2018 (index period). The first prescription date for either a SGLT-2i, GLP-
1RA, or oADM during the index period was referred to as the index date. A diagnosis of T2D was 
defined as having at least one inpatient or outpatient medical claim with an ICD-9-CM of 250.x0, 
250.x2, or ICD-10-CM of E11. 
Only new users, defined as having a prescription claim for either a SGLT-2i, GLP-1RA, 
or oADM with a wash-out period with no prescription claim within the same drug class during the 
12-month baseline period, were included in the study. Patients were divided into three groups using 
a hierarchical approach according to the index medication identified: SGLT-2i, GLP-1RA, and 
oADM. Patients were first assessed for inclusion for either the SGLT-2i or GLP-1RA group. The 
remaining patients were then considered for the oADM group. In cases where patients initiated 
more than one oADM on the day of cohort entry, index medication was selected at random. 
Patients were excluded in the SGLT-2i group if a prescription claim for a GLP-1RA was 
identified in the 12-month baseline period to eliminate probable carryover effects of prior 
competitor use. Consideration of excluding GLP-1RA patients with a prior history of SGLT-2i use 
was not necessary, since the FDA-approval date of the first SGLT-2i marketed in the US, 
canagliflozin, was March 29, 2013. Other exclusion criteria included a diagnosis of T1D. 
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2.4 BASELINE VARIABLES 
Demographic and clinical characteristics were assessed using medical and pharmacy 
claims and EHR data during the 12-month baseline period. Demographic variables include age, 
gender, and race. Age was calculated at the time of index date. Clinical characteristics include 
HbA1c, comorbidities, and glucose-lowering and CV-related medication utilization. 
Comorbidities were identified within medical claims by ICD-9-CM, ICD-10-CM, and Current 
Procedural Terminology (CPT) codes. Relevant comorbidities included history of CVD, MI, 
stroke, TIA, unstable angina, angina pectoris, heart failure, PAD, atrial fibrillation, hypertension, 
CKD, microvascular disease, history of coronary revascularization procedures, dyslipidemia, 
obesity, and conditions found in the in the CCI. CCI was calculated using ICD-9-CM/ICD-10-CM 
diagnosis codes using the University of Manitoba definitions of disorders.49 Medications were 
identified within pharmacy claims using NDC numbers and a string-search of generic and brand 
medication names (Appendix A). A summary of study variables is provided in Table 2.4.1.
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Table 2.4.1 Baseline Variables 
Objective 1: Describe 




between patients who 
are newly initiated on 
SGLT-2is versus 
oADMs, GLP-1RAs 






Level Data Source 
Independent Age at index 




• Count (%) Female  
Categorical Demographics 
Independent Race 
• Count (%) White  
• Count (%) Other  
• Count (%) Unknown 
Categorical Demographics 





between T2D patients 
who are newly 
initiated on SGLT-2is 
versus oADMs, GLP-






Level Data Source 
Independent 
  
CCI score at baseline 








History of CVD at baseline  







History of MI at baseline 







History of stroke at baseline 







History of TIA at baseline 







Unstable angina at baseline 







Angina pectoris at baseline 







Heart failure at baseline 







PAD at baseline 







Atrial fibrillation at baseline 







Hypertension at baseline 







CKD at baseline 








at baseline  







History of coronary 
revascularization at baseline 







Dyslipidemia at baseline 







Obesity at baseline 







Objective 3: Describe 
and determine 
whether baseline 
medication use differ 
between T2D patients 
who are newly 
initiated on SGLT-2is 
versus oADMs, GLP-






Level Data Source 
Independent 
  
Number of antidiabetic 
agents at baseline 







Metformin use at baseline 







DPP-4i use at baseline 







SU use at baseline 





Independent TZD use at baseline 
• Count (%) Yes  
Categorical Prescription Claims 
Independent 
  
Meglinitide use at baseline 







Proportion of patients taking 
insulin at baseline 







ACEi use at baseline 







ARB use at baseline 







Beta blocker use at baseline 







CCB at baseline 







Thiazide use at baseline 







Loop diuretic use at baseline 





Independent Nitrate use at baseline 







Anticoagulant use at baseline 







Antiplatelet use at baseline 





Independent Statin use at baseline 
• Count (%) Yes 
Categorical Prescription Claims 
Objective 4: Describe 
and determine 
whether HbA1c prior 
to initiation of study 
medications differs 
between T2D patients 











Independent HbA1c at baseline 
• Mean (SD) or 
median (IQR) 




ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB 
= calcium-channel blocker; CCI = Charlson Comorbidity Index; CKD = chronic kidney 
disease; CV = cardiovascular; DPP-4i = dipeptidyl peptidase-4 inhibitor; GLP-1RA = 
glucagon-like peptide-1 receptor agonist; HbA1c = hemoglobin A1c; HF = heart failure; oADM 
= antidiabetic medications; MI = myocardial infarction; PAD = peripheral artery disease; 
SGLT-2i = sodium-glucose cotransporter-2 inhibitor; SU = sulfonylurea; TIA = transient 
ischemic attack; TZD = thiazolidinediones 
2.5 OBSERVATION PERIOD 
Follow-up began on the day after index date for all three cohorts. Patients were followed 
using an on-treatment approach until occurrence of a study outcome event, treatment 
discontinuation, switch to a comparator, end of continuous health plan enrollment, or end of the 
study period (December 31, 2018), whichever came first. Treatment discontinuation was defined 
as >60-day persistence gap. Persistence was calculated as the days from the day of first prescription 
claim to the day of first occurrence of prescription fill gap. End of continuous health plan 
enrollment was defined as a gap in continuous health plan enrollment of >45 days. 
2.6 STATISTICAL ANALYSIS 
2.6.1 Baseline Demographic and Clinical Characteristics 
Descriptive statistics were performed on all variables. Continuous variables were described 
in means with standard deviation (SD) or medians with interquartile range (IQR), and categorical 
variables were described in frequency with percentages. Student t-test or Mann-Whitney U test 
were used for continuous measures and chi-square analysis for categorical measures to detect 
differences between groups. Three separate multivariable logistic regression models were used to 
estimate propensity scores and predict the probability of being initiated on a SGLT-2i versus 
oADM, GLP-1RA versus oADM, and SGLT-2i versus GLP-1RA, controlling for all of the listed 
covariates listed in Table 2.1, which were assumed to have an effect on treatment assignment or 
study outcomes. The propensity scores, using a caliper width equal to 0.2 of the standard deviation 
of the logit of the propensity score, were used to 1:1 match patients using a pairwise approach and 
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nearest neighbor greedy algorithm to adjust for confounders and balance baseline patient 
characteristics between treatment groups. Pairwise comparisons of patient demographics and 
clinical characteristics between SGLT-2is versus oADMs, GLP-1RAs versus oADMs and SGLT-
2is versus GLP-1RAs were compared before and after matching. A standardized difference of 
greater than 10% was considered a significant imbalance between groups. 
2.6.2 Cardiovascular Outcomes 
Primary end points were a composite CV outcome comprised of hospitalizations for acute 
MI, stroke, unstable angina, and coronary revascularization, as well as hospitalization for heart 
failure. A composite end point was selected for the primary outcome in order to accumulate more 
events to increase reliable statistical power. The use of singular event end points would require a 
substantially larger sample population than we anticipate from a regional health plan population 
such as SWHP. Secondary end points were the individual components of the CV composite. 
Cumulative incidence of all CV outcome variables were described using Kaplan-Meier 
failure plots and compared using log-rank tests and cox proportional hazards regression models. 
Incident event rates for all outcomes were described for each cohort as the number of first 
occurrence of the outcome events divided by the total number of person-years at risk. Hazard 
Ratios (HR) with 95% confidence intervals (CI) were reported for each outcome for all pairwise 
comparisons. All data manipulation and analyses were performed using SAS version 9.4 software 




Chapter 3: Results 
3.1 STUDY SAMPLE 
From April 1, 2013 through December 31, 2018, a total of 14,100 patients with T2D who 
were new initiators of either an SGLT-2i, GLP-1RA, or oADM were identified. After applying 
study exclusions, 9,477 patients remained: 1,134 SGL-2is initiators, 1,072 GLP-1RA initiators, 
and 7,271 oADM initiators. Figure 3.1 provides the flow chart for patient selection.  
Figure 3.1.1: Patient selection flow chart 
 
GLP-1RA = glucagon-like peptide-1 receptor agonist; oADM = other antidiabetic medication; 
T1D = type 1 diabetes; T2D = type 2 diabetes; SGLT-2i = sodium-glucose cotransporter-2 
inhibitor 
3.2 BASELINE DEMOGRAPHICS AND CLINICAL CHARACTERISTICS 




Table 3.2.1 Baseline Patient Characteristics Pre-Match 



















Age, years, median (IQR) 55.0 (14.0) 60.0 (20.0) <0.001 55.0 (15.0)  60.0 (20.0) <0.001 55.0 (14.0) 55.0 (15.0)  0.27  
Gender                    
Female 554 (48.9) 3501 (48.2)  0.66  640 (57.9) 3501 (48.2) <0.001 554 (48.9) 640 (59.7) <0.001 
Race          
White 442 (39.0) 3863 (53.1) <0.001 433 (40.4) 3863 (53.1) <0.001 442 (39.0) 433 (40.4) 0.50 
Other 106 (9.4) 891 (12.3) 0.005 106 (9.9) 891 (12.3) 0.03 106 (9.4) 106 (9.9) 0.67 
Unknown 586 (51.7) 2517 (34.6) <0.001 533 (49.7) 2517 (34.6) <0.001 586 (51.7) 533 (49.7) 0.36 
Comorbidities   
CCI, median (IQR) 2.0 (2.0) 1.0 (2.0) 0.7706 2.0 (2.0) 1.0 (2.0) 0.002 2.0 (2.0) 2.0 (2.0) 0.01 
CVD History 148 (13.1) 1682 (23.1)  <0.001 154.0 (14.4) 1682 (23.1) <0.001 148 (13.1) 154.0 (14.4) 0.37  
MI 10 (0.9) 145 (2.0) <0.001 12.0 (1.1) 145 (2.0) 0.049 10 (0.9) 12.0 (1.1) 0.57  
Stroke 18 (1.6) 252 (3.5) <0.001 16.0 (1.5) 252 (3.5) 0.001  18 (1.6) 16.0 (1.5)  0.86  
TIA 17 (1.5) 136 (1.9) 0.38  15.0 (1.4) 136 (1.9) 0.28  17 (1.5) 15.0 (1.4)  0.84  
Unstable angina 82 (7.2) 987 (13.6) <0.001 73.0 (6.8) 987 (13.6) <0.001 82 (7.2) 73.0 (6.8)  0.70  
Angina pectoris 11 (1.0) 140 (1.9) 0.02  9.0 (0.8) 140 (1.9) 0.01  11 (1.0) 9.0 (0.8) 0.75  
Heart failure 47 (4.1) 702 (9.7) <0.001 62.0 (5.8) 702 (9.7) <0.001 47 (4.1) 62.0 (5.8) 0.08  
PAD 13 (1.2) 179 (2.5) 0.006  18.0 (1.7) 179 (2.5) 0.12  13 (1.2) 18.0 (1.7)  0.29  
Atrial fibrillation 12 (1.1) 332 (4.6) <0.001 12.0 (1.1) 332 (4.6) <0.001 12 (1.1) 12.0 (1.1)  0.89  
Hypertension 898 (79.2) 5690 (78.3) 0.48  875.0 (81.6) 5690 (78.3) 0.01  898 (79.2) 875.0 (81.6) 0.15  
CKD 48 (4.2) 609 (8.4) <0.001 99.0 (9.2) 609 (8.4) 0.35  48 (4.2) 99.0 (9.2) <0.001 
Microvascular disease 649 (57.2) 2813 (38.7) <0.001 648.0 (60.5) 2813 (38.7) <0.001 649 (57.2) 648.0 (60.5)  0.13  
Dyslipidemia 934 (82.4) 5041 (69.3) <0.001 838.0 (78.2)  5041 (69.3) <0.001 934 (82.4) 838.0 (78.2)  0.01  
Obesity 508 (44.8) 2746 (37.8) <0.001 616.0 (57.5)  2746 (37.8) <0.001 508 (44.8)  616.0 (57.5) <0.001 
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Antidiabetic medications  
Number of antidiabetic 
medications, median (IQR) 
2.0 (2.0) 0.0 (1.0) <0.001 2.0 (2.0) 0.0 (1.0) <0.001 2.0 (2.0) 2.0 (2.0) <0.001 
Metformin 908 (80.1) 1450 (19.9) <0.001 787.0 (73.4) 1450 (19.9) <0.001 908 (80.1) 787.0 (73.4) <0.001  
DPP-4i 358 (31.6) 240 (3.3)  <0.001 252.0 (23.5)  240 (3.3) <0.001 358 (31.6) 252.0 (23.5)  <0.001 
SU 581 (51.2) 992 (13.6) <0.001 477.0 (44.5)  992 (13.6) <0.001 581 (51.2) 477.0 (44.5)  0.002  
TZD 104 (9.2) 76 (1.1) <0.001 69.0 (6.4) 76 (1.1) <0.001 104 (9.2) 69.0 (6.4) 0.02  
Meglinitides 11 (1.0) 5 (0.1) <0.001 8.0 (0.8) 5 (0.1) <0.001 11 (1.0) 8.0 (0.8) 0.57  
Insulin 370 (32.6) 484 (6.7) <0.001 442.0 (41.2) 484 (6.7) <0.001 370 (32.6) 442.0 (41.2) <0.001 
CV-related medications    
ACEi 561 (49.5) 2706 (37.2) <0.001 511.0 (47.7)  2706 (37.2) <0.001 561 (49.5) 511.0 (47.7)  0.40  
ARB 294 (25.9) 1297 (17.8) <0.001 316.0 (29.5)  1297 (17.8) <0.001 294 (25.9) 316.0 (29.5)  0.06  
Beta Blocker 305 (26.9) 2267 (31.2) 0.004  324.0 (30.2)  2267 (31.2) 0.53  305 (26.9) 324.0 (30.2)  0.08  
CCB 230 (20.3) 1509 (20.8) 0.72  248.0 (23.1)  1509 (20.8) 0.07  230 (20.3) 248.0 (23.1)  0.10  
Thiazides 361 (31.8) 2002 (27.5) 0.003  396.0 (36.9)  2002 (27.5) <0.001 361 (31.8) 396.0 (36.9)  0.01  
Loop Diuretic 85 (7.5) 812 (11.2) 0.002  110.0 (10.3)  812 (11.2) 0.38  85 (7.5) 110.0 (10.3)  0.02  
Nitrate 45 (4.0) 347 (4.8) 0.23  52.0 (4.9) 347 (4.8) 0.91  45 (4.0) 52.0 (4.9) 0.31  
Anticoagulant 29 (2.6) 333 (4.6) 0.002  24.0 (2.2) 333 (4.6) <0.001  29 (2.6) 24.0 (2.2) 0.63  
Antiplatelet 82 (7.2) 453 (6.2) 0.20  85.0 (7.9) 453 (6.2) 0.04  82 (7.2) 85.0 (7.9)  0.54  
Statin 786 (69.3) 3447 (47.4) <0.001 708.0 (66.0) 3447 (47.4) <0.001 786 (69.3) 708.0 (66.0) 0.10  
Hemoglobin A1C  
Patients with HbA1c  
Available 
334 (29.5) 2564 (36.3) <0.001  304.0 (28.4) 2564 (35.3) <0.001 334 (29.5)  304.0 (28.4)  0.57  
HbA1c, median (IQR) 8.8 (1.9) 7.6 (2.1) <0.001 8.4 (1.9) 7.6 (2.1) <0.001 8.8 (1.9) 8.4 (1.9) 0.02  
Data are n (%) unless otherwise stated. 
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = Calcium channel blocker; CCBs = 
calcium-channel blocker; CCI = Charlson Comorbidity Index; CKD = chronic kidney disease; CV = cardiovascular; CVD = 
cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = 
hemoglobin A1c; IQR = interquartile range; oADM = other antidiabetic medication; MI = myocardial infarction; PAD = peripheral 




3.2.1 Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Antidiabetic Medication 
Classes 
Prior to propensity score matching, patients initiating SGLT-2is were younger (median 
[IQR]: 55.0 [14.0] versus 60.0 [20.0] years; p<0.001), had lower prevalence of CVD (13.1% versus 
23.1%; p<0.001) and CKD (4.2% versus 8.4%; p<0.001), lower baseline utilization of beta-
blockers (26.9% versus 31.2%; p=0.004), loop diuretics (7.5% versus 11.2%; p<0.001), and 
anticoagulants (2.6% versus 4.6%; p=0.002) compared to patients initiating oADMs. However, 
they were more likely to have microvascular disease (57.2% versus 38.7%; p<0.001), dyslipidemia 
(82.4% versus 69.3%; p<0.001), obesity (50.4% versus 42.7%; p<0.001), had higher baseline 
utilization of antihyperglycemic agents (median [IQR]: 2.0 [2.0] versus 0.0 [1.0]; p<0.001), ACEis 
(49.5% versus 37.2%; p<0.001), ARBs (25.9% versus 17.8%; p<0.001), statins (69.3% versus 
47.4%; p<0.001), and had higher HbA1c (median [IQR]: 8.8 [1.9] versus 7.6 [2.1] mg/dL; 
p<0.001). 
3.2.2 Glucagon-like Peptide-1 Receptor Agonists Versus Other Antidiabetic Medication 
Classes 
Prior to propensity score matching, patients initiating GLP-1RAs were younger (median 
[IQR]: 55.0 [15.0] versus 60.0 [20.0] years; p<0.001), more female (59.7% versus 48.2%; 
p<0.001), had lower prevalence of CVD (14.4% versus 23.1%; p<0.001), and lower baseline 
utilization of anticoagulants (2.2% versus 4.6%; p=0.002) and antiarrhythmics (2.5% versus 3.7%; 
p=0.048) compared to patients initiating oADMs. However, they were more likely to have higher 
CCI scores (median [IQR]: 2.0 [2.0] versus 1.0 [2.0]; p<0.002), higher prevalence of hypertension 
(81.6% versus 78.3%; p=0.01), microvascular disease (57.2% versus 38.7%; p<0.001), 
dyslipidemia (78.2% versus 69.3%; p<0.001), obesity (57.5% versus 42.7%; p<0.001), had higher 
baseline utilization of antihyperglycemic agents (median [IQR]: 2.0 [2.0] versus 0.0 [1.0]; 
p<0.001), ACEis (47.7% versus 37.2%; p<0.001), ARBs (29.5% versus 17.8%; p<0.001), thiazide 
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diuretics (36.9% versus 27.5%; p<0.001), statins (66.0% versus 47.4%; p<0.001), and had higher 
HbA1c (median [IQR]: 8.4 [1.9] versus 7.6 [2.1] mg/dL; p<0.001). 
3.2.3 Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 
Receptor Agonists 
Prior to propensity score matching, patients initiating SGLT-2is were more female (48.9% 
versus 59.7%; p<0.001), had lower prevalence of CKD (4.2% versus 9.2%; p<0.001), nephropathy 
(41.5% versus 46.6%; p=0.02), and lower baseline utilization of sulfonylureas (51.2% versus 
44.5%; p0.002), insulin (32.6% versus 41.2%; p<0.001), thiazide diuretics (31.8% versus 36.9%; 
p=0.02), and loop diuretics (7.5% versus 10.3%; p=0.02), compared to patients initiating GLP-
1RAs. However, they were more likely to had higher prevalence of dyslipidemia (82.4% versus 
78.2%; p=0.01), had higher baseline utilization of metformin (80.1%% versus 73.4%; p<0.001), 
DPP-4is (31.6% versus 23.5%; p<0.001), and TZD (9.2% versus 6.4%; p=0.02), and had higher 
HbA1c (median [IQR]: 8.8 [1.9] versus 8.4 [1.9] mg/dL; p=0.02). 
3.3 CARDIOVASCULAR OUTCOMES 
Table 3.3.1 shows post-match comparisons of baseline characteristics within each cohort.
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Table 3.3.1 Baseline Patient Characteristics Post-Match 
Variables  
n=patients 




















Age, years, median (IQR) 56.0 (14.0) 58.0 (18.0)  -0.1 55.0 (14.0)  56.0 (16.0)  0.1 55.0 (14.0)  55.0 (15.0) 0.1 
Gender                   
Female 48.8  48.8 0.0  58.0  58.0 0.0 57.7  57.7 0.0 
Comorbidities 
CCI, median (IQR) 2.0 (2.0)  2.0 (2.0) -0.1 2.0 (2.0) 2.0 (2.0) 0.0 2.0 (2.0) 2.0 (15.0) 0.0 
History of CVD 14.8  17.9  0.0 15.3  16.3  0.0 12.0  12.8  0.0 
MI 0.9  0.9  0.1 1.4  1.0  0.0 0.8  1.2  0.0 
Stroke 2.0  2.1  0.0 1.2  1.4  0.0 1.4  1.5  0.0 
Unstable angina 8.5  10.4  0.1 8.1  9.0  0.0 6.3  7.0  0.0 
Heart failure 4.5  5.8  0.1 6.0  6.8  0.0 4.4  4.1  0.0 
PAD 1.4  1.7  0.0 1.8  1.7  0.0 1.2  1.3  0.0 
Atrial fibrillation 1.4  1.2  0.0 1.5  1.6  0.01 1.0  1.1  0.0 
Hypertension 79.8  80.9  0.0 81.0  80.3  0.0 79.0  80.3  0.0 
CKD 4.8  6.5  0.1 9.1  9.5  0.0 4.5  4.9  0.0 
Microvascular Disease 51.7  49.7  0.0 55.0  50.0  0.1 58.4  58.3  0.0 
Dyslipidemia 81.2  82.2  0.1 76.6  76.9  0.0 80.6  79.0  0.0 
Obesity 48.6  46.9  0.0 58.2  58.7  0.0 54.6  59.1  0.1 
Antidiabetic medications 
Number of antidiabetic 
medications, median (IQR) 
2.0 (1.0) 2.0 (1.0) 0.0 2.0 (1.0) 2.0 (1.0) 0.0 2.0 (2.0) 2.0 (2.0) 0.1 
Metformin 73.0  74.4  0.0 66.8  70.4  0.1 78.8  77.5  0.0 
DPP-4i 22.2  18.6  -0.1 18.4  16.3  0.1 29.7  25.5  0.1 
SU 44.2  44.9  0.0 38.8  38.3  0.0 49.7  47.4  0.1 
TZD 5.0  4.8  0.0 5.0  4.1  0.1 9.1  7.2  0.1 
Insulin 24.4  24.7  0.0 31.2  27.7  0.1 34.2  37.4  0.1 
CV-related medications 
ACEi 49.2  50.4  0.0 47.0  47.5  0.0 48.8  47.3  0.0 
 44 
 
ARB 25.3  25.0  0.0 27.4  27.4  0.0 26.4  27.8  0.0 
Beta Blocker 20.9  22.4  0.1 31.3  31.2  0.0 26.6  28.1  0.0 
CCB 20.9  22.4  0.0 22.5  23.1  0.0 20.4  22.0  0.1 
Thiazide Diuretic 32.9  32.3  0.0 36.3  34.2  0.0 33.2  34.6  0.0 
Loop Diuretic 2.8  2.7  0.1 11.7  12.4  0.0 7.9  8.2  0.0 
Anticoagulant 2.8  2.7  0.0 2.7  2.3  0.0 2.2  2.0  0.0 
Statin 68.2  70.3  0.0 62.5  63.6  0.0 68.3  66.1  0.1 
Data are n (%) unless otherwise stated. 
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = Calcium channel blocker; CCBs = 
calcium-channel blocker; CCI = Charlson Comorbidity Index; CKD = chronic kidney disease; CV = cardiovascular; CVD = 
cardiovascular disease; DPP-4i = dipeptidyl peptidase-4 inhibitor; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = 
hemoglobin A1c; IQR = interquartile range; oADM = other antidiabetic medication; MI = myocardial infarction; PAD = peripheral 




After propensity score matching, relevant patient characteristics included in all three propensity 
score models were well balanced with standardized differences ≤10%. There were 815 matched 
pairs in Cohort 1 (SGLT-2i versus oADM), 817 matched pairs in Cohort 2 (GLP-RA versus 
oADM), and 947 matched pairs in Cohort 3 (SGLT-2i versus GLP-1RA). 
3.3.1 Primary Cardiovascular Outcomes 
 Table 3.3.1.1 shows the associated risks for the composite CV outcome and hospitalization 
for heart failure for patients in each pairwise propensity score matched cohort.
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Table 3.3.1.1 Risk of composite cardiovascular outcome and hospitalization for heart failure for patients within each pairwise 












CV Composite Endpoint                   
Follow-up, years 1058 1530  921 1521  1249 1090  
Incidence rate* 7.0 8.5   7.6 8.2   6.2 6.2   
Hazard Ratio (95% CI) 0.69 (0.52-0.92)   0.01 0.70 (0.52-0.94)   0.02 
1.03 (0.72-
1.43) 
  0.86 
Heart failure hospitalization                 
Follow-up, years 1096 1679  956 1629  1289 1124  
Incidence rate* 4.7 6.3   6.4 6.9   4.1 4.9   
Hazard Ratio (95% CI) 0.66 (0.47-0.93)   0.02 0.79 (0.57-1.08)   0.14 
0.88 (0.60-
1.29) 
  0.51 
*Incidence rate per 100 person-years 
CI = confidence interval; CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; oADM = other antidiabetic 
medication; SGLT-2i = sodium-glucose cotransporter-2 inhibitor
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For the primary composite CV endpoint, the incidence rate for patients who were newly initiated 
on SGLT-2is compared to oADMs was 7.0 versus 8.5 events per 100 person-years with a 
significantly lower cumulative risk (HR 0.69, 95% CI: 0.52-0.92; p=0.01). Figure 3.3.1.1 shows 
the comparison of primary CV outcome event curves for SGLT-2is compared to oADMs.
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Figure 3.3.1.1 Composite cardiovascular outcome and hospitalization for heart failure event curves for patients newly initiated on 
sodium-glucose cotransporter-2 inhibitors versus other antidiabetic medications 
  
CV = cardiovascular; oADM = other antidiabetic medication; SGLT-2i = sodium-glucose cotransporter-2 inhibitor 



























Cumulative Incidence of the CV Composite Endpoint Cumulative Incidence of Hospitalization for Heart Failure 
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Mean follow-up time for the composite CV endpoint for SGLT-2is versus oADMs was 473 and 
683 days, respectively. Separation in event curves occurred early and was significant (log-rank test 
p=0.01). For hospitalization for heart failure the incidence rate for patients who initiated SGLT-
2is compared to oADMs was 4.7 versus 6.3 events per person-years with a significantly lower 
cumulative risk (HR 0.66, 95% CI: 0.47-0.93; p=0.02). Mean follow-up time for hospitalization 
for heart failure for SGLT-2is versus oADMs was 490 and 750 days, respectively. Separation in 
event curves occurred early and was significant (log-rank test p=0.02). 
 When comparing patients who were newly initiated on GLP-1RAs compared to oADMs, 
the incidence rate for the primary composite CV endpoint was 7.6 versus 8.2 events per 100 
person-years with a significantly lower cumulative risk of HR 0.69, 95% CI: 0.52-0.92; p=0.01). 




Figure 3.3.1.2 Composite cardiovascular outcome and hospitalization for heart failure event curves for patients newly initiated on 
glucagon-like peptide-1 receptor agonists versus other antidiabetic medications 
  





























Time to Event (Days) 
Cumulative Incidence of the CV Composite Endpoint Cumulative Incidence of Hospitalization for Heart Failure 
Time to Event (Days) 
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Mean follow-up time for the composite CV endpoint for GLP-1RAs versus oADMs was 413 and 
681 days, respectively. Separation in event curves occurred early and was significant (log-rank test 
p=0.02). For hospitalization for heart failure, the incidence rate for patients who initiated GLP-
1RAs compared to oADMs was 6.4 versus 6.9 events per person-years with no significant 
difference in cumulative risk HR 0.66, 95% CI: 0.47-0.93; p=0.02). Mean follow-up time for 
hospitalization for heart failure for GLP-1RAs versus oADMs was 428 and 730 days, respectively. 
There were no significant differences in event curves (log-rank test p=0.14). 
When comparing patients who were newly imitated on SGLT-2is compared to GLP-1RAs, 
there were no significant differences in the primary CV outcomes. For the primary composite CV 
endpoint, the incidence rate for patients who initiated SGLT-2is compared to SGLT-2is was 6.2 
versus 6.2 events per 100 person-years with no significant difference in cumulative risk (HR 1.03, 
95% CI: 0.72-1.43; p=0.86). Figure 3.3.1.3 shows the comparison of primary CV outcome event 
curves for SGLT-2s compared to GLP-1RAs. 
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Figure 3.3.1.3 Composite cardiovascular outcome and hospitalization for heart failure event curves for patients newly initiated on 
sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists 
  
CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; SGLT-2i = sodium-glucose cotransporter-2 inhibitor

































Mean follow-up time for the composite CV endpoint for SGLT-2is versus GLP-1RAs was 481 
and 420 days, respectively. There were no significant differences in event curves (log-rank test 
p=0.86). For hospitalizations for heart failure, the incidence rate for patients who initiated SGLT-
2is compared to GLP-1RAs was 4.1 versus 4.9 events per person-years with no significant 
difference in cumulative risk (HR 0.88, 95% CI: (0.60-1.29); p=0.51). Mean follow-up time for 
the composite CV endpoint for SGLT-2is versus GLP-1RAs was 497 and 433 days, respectively. 




3.3.2 Secondary Cardiovascular Outcomes 
Table 3.3.2.1 shows the associated risks for the secondary cardiovascular outcomes, 
unstable angina requiring hospitalization, stroke, MI, and coronary revascularization for patients 
in each pairwise propensity score matched cohort.   
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CV Outcomes SGLT-2i oADM p-value GLP-1RA oADM p-value SGLT-2i GLP-1RA p-value 
Unstable angina requiring hospitalization                 
Follow-up, years 1080 1572  938 1559  1270 1106  
Incidence rate* 4.7 6.4   5.3 6.4   4.3 4.4   
Hazard Ratio (95% CI) 0.58 (0.41-0.82)   0.002 0.59 (0.42-0.83)   0.003 1.01 (0.69-1.49)   0.96 
Myocardial infarction                 
Follow-up, years 1159 1834  1015 1802  1347 1179  
Incidence rate* 1.2 1.0   1.7 1.5   1.3 1.4   
Hazard Ratio (95% CI) 1.18 (0.58-2.4)   0.64 0.98 (0.53-1.82)   0.95 1.01 (0.52-1.99)   0.97 
Stroke                 
Follow-up, years 1162 1808  1014 1794  1353 1177  
Incidence rate* 1.5 1.8   1.2 1.2   1.1 0.8   
Hazard Ratio (95% CI) 0.79 (0.43-1.44)   0.44 0.90 (0.44-1.85)   0.78 1.43 (0.62-3.26)   0.40 
Coronary revascularization                 
Follow-up, years 1146 1823  1010 1803  1335 1177  
Incidence rate* 1.4 1.3   1.5 1.2   1.3 1.3   
Hazard Ratio (95% CI) 1.23 (0.64-2.37)   0.53 1.36 (0.69-2.67)   0.37 1.02 (0.52-2.03)   0.95 
*Incidence rate per 100 person-years 
CI = confidence interval; CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; oADM = other antidiabetic 
medication; SGLT-2i = sodium-glucose cotransporter-2 inhibitors
 56 
 
When comparing patients newly initiated on SGLT-2is compared to oADMs, the incidence rate 
for unstable angina requiring hospitalization was 4.7 versus 6.4 events per 100 person-years with 
a significantly lower cumulative risk (HR 0.58, 95% CI: 0.41-0.82; p=0.002). Figure 3.3.2.1 shows 




Figure 3.3.2.1 Secondary cardiovascular outcomes event curves for patients newly initiated on sodium-glucose cotransporter-2 
inhibitors versus other antidiabetic medications 
  
  
CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; oADM = other antidiabetic medication; SGLT-2i = 





























































Time to Event (Days) Time to Event (Days) 
Time to Event (Days) Time to Event (Days) 
Cumulative Incidence of Unstable Angina Requiring Hospitalization Cumulative Incidence of Stroke 
Cumulative Incidence of Myocardial Infarction Cumulative Incidence of Coronary Revascularization 
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Mean follow-up time for unstable angina requiring hospitalization for SGLT-2is versus oADMs 
was 483 and 703 days, respectively. Separation in event curves occurred early and was significant 
(log-rank test p=0.002). For all other secondary outcomes, there were no significant differences 
between SGLT-2is versus oADMs. 
When comparing patients newly initiated on GLP-1RAs compared to oADMs, the 
incidence rate for unstable angina requiring hospitalization was 5.3 versus 6.4 events per 100 
person-years with a significantly lower cumulative risk (HR 0.58, 95% CI: 0.42-0.83; p=0.003). 
Figure 3.3.2.2 shows the comparison of secondary cardiovascular outcome event curves for GLP-
1RAs compared to oADMs. 
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Figure 3.3.2.2 Secondary cardiovascular outcomes event curves for patients newly initiated on glucagon-like peptide-1 receptor 
agonists versus other antidiabetic medications 
  
  
CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; oADM = other antidiabetic medication; SGLT-2i = 
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Mean follow-up time for unstable angina requiring hospitalization for GLP-1RAs versus oADMs 
was 420 and 699 days, respectively. Separation in event curves occurred early and was significant 
(log-rank test p=0.002). For all other secondary outcomes, there were no significant differences 
between SGLT-2is versus oADMs. 
When comparing patients newly initiated on SGLT-2is compared to GLP-1RAs , the 
incidence rate for unstable angina requiring hospitalization For the unstable angina requiring 
hospitalization, the incidence rate for patients initiating GLP-1RAs compared to oADMs was 5.3 
versus 6.4 events per 100 person-years with a significantly lower cumulative risk (HR 0.58, 95% 
CI: 0.42-0.83; p=0.003). Figure 3.3.2.3 shows the comparison of secondary cardiovascular 
outcome event curves for GLP-1RAs compared to oADMs.
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Figure 3.3.2.3 Secondary cardiovascular outcomes event curves for patients newly initiated on sodium-glucose cotransporter-2 
inhibitors versus glucagon-like peptide-1 receptor agonists 
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Mean follow-up time for unstable angina requiring hospitalization for GLP-1RAs versus oADMs 
was 420 and 699 days, respectively. Separation in event curves occurred early and was significant 
(log-rank test p=0.002). For all other secondary outcomes, there were no significant differences 
between SGLT-2is versus oADMs. 
3.4 SUMMARY OF RESULTS 
Objectives and Alternate Hypotheses (H1) Result 
Objective 1 
Describe and determine whether baseline demographics differ between T2D patients newly 
initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, and SGLT-2is versus GLP-1RAs. 
H11.1: The difference in age between patients newly initiated on SGLT-2is 
versus oADMs is statistically significant. 
Failed to reject 
H11.2: The difference in age between patients newly initiated on GLP-
1RAs versus oADMs is statistically significant. 
Failed to reject 
H11.3: The difference in age between patients newly initiated on SGLT2is 
versus GLP-1RAs is statistically significant. 
Rejected 
H11.4: The difference in gender between patients newly initiated on SGLT-
2is versus oADMs is statistically significant. 
Failed to reject 
H11.5: The difference in gender between patients newly initiated on GLP-
1RAs versus oADMs is statistically significant. 
Rejected 
H11.6: The difference in gender between patients newly initiated on SGLT-
2is versus GLP-1RAs is statistically significant. 
Failed to reject 
H11.7: The difference in the proportion of patients of white race between 
patients newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Rejected 
H11.8: The difference in the proportion of patients of white race between 





Objectives and Alternate Hypotheses (H1) Result 
H11.9: The difference in the proportion of patients of white race between 
patients newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Failed to reject 
H11.10: The difference in the proportion of patients of other race 
between patients newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Rejected 
H11.11: The difference in the proportion of patients of other race 
between patients newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H11.12: The difference in the proportion of patients of other race 
between patients newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H11.13: The difference in the proportion of patients of unknown race 
between patients newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Rejected 
H11.14: The difference in the proportion of patients of unknown race 
between patients newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H11.15: The difference in the proportion of patients of unknown race 
between patients newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
Objective 2 
Describe and determine whether baseline prevalence of comorbidities differ between T2D 
patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, SGLT-2is versus 
GLP-1RAs. 
H12.1: The difference in CCI scores between those who are newly initiated 
on SGLT-2is versus oADMs is statistically significant. 
Rejected 
H12.2: The difference in CCI scores between those who are newly initiated 
on GLP-1RAs versus oADMs is statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H12.3: The difference in CCI scores between those who are newly initiated 
on SGLT-2is versus GLP-1RAs is statistically significant. 
Failed to reject 
H12.4: The difference in the proportion of patients with a history of CVD 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.5: The difference in the proportion of patients with a history of CVD 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.6: The difference in the proportion of patients with a history of CVD 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.7: The difference in the proportion of patients with a history of MI 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.8: The difference in the proportion of patients with a history of MI 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.9: The difference in the proportion of patients with a history of MI 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.10: The difference in the proportion of patients with a history of 
stroke between those who are newly initiated on SGLT-2is versus oADMs 
is statistically significant. 
Failed to reject 
H12.11: The difference in the proportion of patients with a history of 
stroke between those who are newly initiated on GLP-1RAs versus oADMs 
is statistically significant. 
Failed to reject 
H12.12: The difference in the proportion of patients with a history of 
stroke between those who are newly initiated on SGLT-2is versus GLP-
1RAs is statistically significant. 
Rejected 
H12.13: The difference in the proportion of patients with a history of TIA 





Objectives and Alternate Hypotheses (H1) Result 
H12.14: The difference in the proportion of patients with a history of TIA 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H12.15: The difference in the proportion of patients with a history of TIA 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.16: The difference in the proportion of patients with unstable angina 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.17: The difference in the proportion of patients with unstable angina 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.18: The difference in the proportion of patients with unstable angina 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.19: The difference in the proportion of patients with angina pectoris 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.20: The difference in the proportion of patients with angina pectoris 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.21: The difference in the proportion of patients with angina pectoris 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.22: The difference in the proportion of patients with heart failure 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.23: The difference in the proportion of patients with heart failure 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H12.24: The difference in the proportion of patients with heart failure 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.25: The difference in the proportion of patients with PAD between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
H12.26: The difference in the proportion of patients with PAD between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Rejected 
H12.27: The difference in the proportion of patients with PAD between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Rejected 
H12.28: The difference in the proportion of patients with atrial fibrillation 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.29: The difference in the proportion of patients with atrial fibrillation 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.30: The difference in the proportion of patients with atrial fibrillation 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H12.31: The difference in the proportion of patients with hypertension 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Rejected 
H12.32: The difference in the proportion of patients with hypertension 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.33: The difference in the proportion of patients with hypertension 





Objectives and Alternate Hypotheses (H1) Result 
H12.34: The difference in the proportion of patients with CKD between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
H12.35: The difference in the proportion of patients with CKD between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Rejected 
H12.36: The difference in the proportion of patients with CKD between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Failed to reject 
H12.37: The difference in the proportion of patients with microvascular 
disease between those who are newly initiated on SGLT-2is versus oADMs 
is statistically significant. 
Failed to reject 
H12.38: The difference in the proportion of patients with microvascular 
disease between those who are newly initiated on GLP-1RAs versus 
oADMs is statistically significant. 
Failed to reject 
H12.39: The difference in the proportion of patients with microvascular 
disease between those who are newly initiated on SGLT-2is versus GLP-
1RAs is statistically significant. 
Rejected 
H12.40: The difference in the proportion of patients with dyslipidemia 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H12.41: The difference in the proportion of patients with dyslipidemia 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H12.42: The difference in the proportion of patients with dyslipidemia 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H12.43: The difference in the proportion of patients with obesity between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H12.44: The difference in the proportion of patients with obesity between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Failed to reject 
H12.45: The difference in the proportion of patients with obesity between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Failed to reject 
Objective 3 
Describe and determine whether baseline medication use differ between T2D patients newly 
initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, SGLT-2is versus GLP-1RAs. 
H13.1: The difference in the number of antidiabetic medications used 
between patients newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
H13.2: The difference in the number of antidiabetic medications used 
between patients newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.3: The difference in the number of antidiabetic medications used 
between patients newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.4: The difference in the proportion of patients taking metformin 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.5: The difference in the proportion of patients taking metformin 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.6: The difference in the proportion of patients taking metformin 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.7: The difference in the proportion of patients taking DPP-4is 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H13.8: The difference in the proportion of patients taking DPP-4is 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.9: The difference in the proportion of patients taking DPP-4is 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.10: The difference in the proportion of patients taking sulfonylureas 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.11: The difference in the proportion of patients taking sulfonylureas 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.12: The difference in the proportion of patients taking sulfonylureas 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.13: The difference in the proportion of patients taking TZDs between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
H13.14: The difference in the proportion of patients taking TZDs between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Failed to reject 
H13.15: The difference in the proportion of patients taking TZDs between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Failed to reject 
H13.16: The difference in the proportion of patients taking meglinitides 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.17: The difference in the proportion of patients taking meglinitides 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H13.18: The difference in the proportion of patients taking meglinitides 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.19: The difference in the proportion of patients taking insulin 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.20: The difference in the proportion of patients taking insulin 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.21: The difference in the proportion of patients taking insulin 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.22: The difference in the proportion of patients taking ACEis, 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.23: The difference in the proportion of patients taking ACEis, 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.24: The difference in the proportion of patients taking ACEis, 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.25: The difference in the proportion of patients taking ARBs between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Failed to reject 
H13.26: The difference in the proportion of patients taking ARBs between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Failed to reject 
H13.27: The difference in the proportion of patients taking ARBs between 





Objectives and Alternate Hypotheses (H1) Result 
H13.28: The difference in the proportion of patients taking beta blockers 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.29: The difference in the proportion of patients taking beta blockers 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H13.30: The difference in the proportion of patients taking beta blockers 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.31: The difference in the proportion of patients taking CCBs between 
those who are newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Rejected 
H13.32: The difference in the proportion of patients taking CCBs between 
those who are newly initiated on GLP-1RAs versus oADMs is statistically 
significant. 
Rejected 
H13.33: The difference in the proportion of patients taking CCBs between 
those who are newly initiated on SGLT-2is versus GLP-1RAs is statistically 
significant. 
Rejected 
H13.34: The difference in the proportion of patients taking thiazides 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.35: The difference in the proportion of patients taking thiazides 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.36: The difference in the proportion of patients taking thiazides 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.37: The difference in the proportion of patients taking loop diuretics 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H13.38: The difference in the proportion of patients taking loop diuretics 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H13.39: The difference in the proportion of patients taking loop diuretics 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Failed to reject 
H13.40: The difference in the proportion of patients taking nitrates 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Rejected 
H13.41: The difference in the proportion of patients taking nitrates 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H13.42: The difference in the proportion of patients taking nitrates 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.43: The difference in the proportion of patients taking anticoagulants 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.44: The difference in the proportion of patients taking anticoagulants 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.45: The difference in the proportion of patients taking anticoagulants 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.46: The difference in the proportion of patients taking antiplatelets 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Rejected 
H13.47: The difference in the proportion of patients taking antiplatelets 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
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Objectives and Alternate Hypotheses (H1) Result 
H13.48: The difference in the proportion of patients taking antiplatelets 
between those who are newly initiated on SGLT-2is versus GLP-1RAs is 
statistically significant. 
Rejected 
H13.49: The difference in the proportion of patients taking statins 
between those who are newly initiated on SGLT-2is versus oADMs is 
statistically significant. 
Failed to reject 
H13.50: The difference in the proportion of patients taking statins 
between those who are newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Failed to reject 
H13.51: The difference in the proportion of patients taking statins 




Describe and determine whether HbA1c prior to initiation of study medications differs 
between T2D patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, 
SGLT-2is versus GLP-1RAs. 
H14.1: The difference in proportion of patients missing HbA1c values 
newly initiated on SGLT-2is versus oADMs is statistically significant. 
Failed to reject 
H14.2: The difference in proportion of patients missing HbA1c values 
newly initiated on GLP-1RAs versus oADMs is statistically significant. 
Failed to reject 
H14.3: The difference in proportion of patients missing HbA1c values 
newly initiated on SGLT-2is versus GLP-1RAs is statistically significant. 
Rejected 
H14.4: The difference in HbA1c between patients newly initiated on SGLT-
2is versus oADMs is statistically significant. 
Failed to reject 
H14.5: The difference in HbA1c between patients newly initiated on GLP-
1RAs versus oADMs is statistically significant. 
Failed to reject 
H14.6: The difference in HbA1c between patients newly initiated SGLT-2is 
versus GLP-1RAs is statistically significant. 




Objectives and Alternate Hypotheses (H1) Result 
Determine whether the cumulative incidence or hazard of CV outcomes differ between T2D 
patients newly initiated on SGLT-2is versus oADMs, GLP-1RAs versus oADMs, SGLT-2is versus 
GLP-1RAs. 
H15.1: The difference in the cumulative incidence or hazard of the 
composite CV endpoint between patients newly initiated on SGLT-2is 
versus oADMs is statistically significant. 
Failed to reject 
H15.2: The difference in the cumulative incidence or hazard of the 
composite CV endpoint between patients newly initiated on GLP-1RAs 
versus oADMs is statistically significant. 
Failed to reject 
H15.3: The difference in the cumulative incidence or hazard of the 
composite CV endpoint between patients newly initiated on SGLT-2is 
versus GLP-1RAs is statistically significant. 
Rejected 
H15.4 The difference in the cumulative incidence or hazard of 
hospitalizations for heart failure between patients newly initiated on 
SGLT-2is versus oADMs is statistically significant. 
Failed to reject 
H15.5: The difference in the cumulative incidence or hazard of 
hospitalizations for heart failure between patients newly initiated on GLP-
1RAs versus oADMs is statistically significant. 
Rejected 
H15.6: The difference in the cumulative incidence or hazard of 
hospitalizations for heart failure between patients newly initiated on 
SGLT-2is versus GLP-1RAs is statistically significant. 
Rejected 
H15.7: The difference in the cumulative incidence or hazard of MI 
between patients newly initiated on SGLT-2is versus oADMs is statistically 
significant. 
Rejected 
H15.8: The difference in the cumulative incidence or hazard of MI 
between patients newly initiated on GLP-1RAs versus oADMs is 
statistically significant. 
Rejected 
H15.9: The difference in the cumulative incidence or hazard of MI 





Objectives and Alternate Hypotheses (H1) Result 
H15.10: The difference in the cumulative incidence or hazard of unstable 
angina requiring hospitalization between patients newly initiated on 
SGLT-2is versus oADMs is statistically significant. 
Failed to reject 
H15.11: The difference in the cumulative incidence or hazard of unstable 
angina requiring hospitalization between patients newly initiated on GLP-
1RAs versus oADMs is statistically significant. 
Failed to reject 
H15.12: The difference in the cumulative incidence or hazard of unstable 
angina requiring hospitalization between patients newly initiated on 
SGLT-2is versus GLP-1RAs is statistically significant. 
Rejected 
ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = 
Calcium channel blocker; CCBs = calcium-channel blocker; CCI = Charlson Comorbidity Index; 
CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DPP-4i = 
dipeptidyl peptidase-4 inhibitor; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = 
hemoglobin A1c; oADM = other antidiabetic medication; MI = myocardial infarction; PAD = 
peripheral artery disease; SGLT-2i = sodium-glucose cotransporter-2 inhibitor; TIA = transient 
ischemic attack; TZD = thiazolidinediones
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Chapter 4: Discussion and Conclusion 
4.1 DISCUSSION 
This is the first population-based real-world study to evaluate the differences in patient 
characteristics and the comparative effectiveness of initiating SGLT-2is, GLP-1RAs, or oADMs 
in regards to CV outcomes in an integrated delivery network setting. In our institution, T2D 
patients who were initiated on SGLT-2is and GLP-1RAs were relatively similar. Patients initiating 
GLP-1RAs had higher prevalence of CKD and obesity at baseline, which is likely as a result of 
the contraindications and precautions of use in patients with renal impairment associated with 
SGLT-2is and the preference of GLP-1RAs over SGLT-2is for minimizing weight gain or 
promoting weight loss. In addition, differences in baseline antidiabetic use were observed between 
these groups with SGLT-2i patients had higher utilization of other oral agents. One reasonable 
explanation may be due to patients being switch to SGLT-2is due to the relatively easier oral to 
oral conversion in therapy, whereas the conversion from an oral agent to an injectable such as a 
GLP-1RA may not be preferred by most patients. Insulin use was higher for patients initiated on 
GLP-1RAs compared to SGLT-2is, likely explained as a result of the increasing popularity of 
combining both agents for their synergistic effects on glucose-lowering and opposing weight 
effects. This is the basis of the development of GLP-1RA and insulin combination products. 
In contrast, patients who were initiated on SGLT-2is and GLP-1RAs compared to oADMs 
showed significant differences in baseline characteristic. These patients tended to be younger with 
a lower prevalence of CVD but did have higher prevalence of microvascular disease. This is 
surprising since based on our estimate of diabetes severity based on multiple proxy indicators, it 
would seem that most of our patients who were newly initiated on oADMs had low severity and 
may have been more recently diagnosed with T2D, given that over 50% of our oADM group were 
new initiators of metformin, had less antidiabetic medications at baseline, and had lower HbA1c 
values. However, it is important to note that almost 50% of our patients had missing HbA1c values. 
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Nevertheless, our method of propensity score matching each pairwise comparison group allowed 
us to evenly distribute measured covariates between each group. 
Our findings showed that both SGLT-2is and GLP-1RAs significantly reduced the risk of 
the composite CV endpoint comprised of MI, stroke, unstable angina, and coronary 
revascularization compared to oADMs by 31% and 30%, respectively, in a population of patients 
with T2D who had a low prevalence of established CVD. The majority of CVOTs that have been 
completed to date recruited a high CV risk population with almost all patients having established 
CVD in order to accumulate enough events to allow for a meaningful estimate of the risk, which 
is not representative of the general T2D population. 
While it is difficult to compare our results with most of the CVOTs for these agents due to 
the lack of access to mortality data, we can at least compare some of the data regarding nonfatal 
events. Our study showed that SGLT-2is reduced the risk of heart failure hospitalization by 34%, 
which is in line with what was seen for empagliflozin in EMPA-REG OUTCOME, canagliflozin 
in CANVAS, and dapagliflozin in DECLARE-TIMI 58 at 35%, 33%, and 27%, respectively.37–39 
However, almost all of the patients that were included in those trials either had established CVD, 
with the exception of DECLARE-TIMI 58 which also included patients with only CV risk factors, 
while the majority (greater than 80%) of the patients in our study did not have any history of CVD 
with less than 9% having a history of heart failure. This provides more evidence in support of 
considering these agents early in the treatment decision algorithm for primary prevention of CVD, 
specifically for heart failure. For GLP-1RAs, our results showed a non-significant reduction in 
heart failure hospitalization compared to oADMs, which is also consistent in what is seen in the 
GLP-1RA CVOTs. When comparing the reduction of MACE risk of both agents compared to 
placebo in CVOTs, the Kaplan-Meier curves were seen to separate early within the first few 
months for SGLT-2i agents, whereas the curves start to separate after about 12 months.50 This may 
suggest that CV benefit for SGLT-2is are primarily driven by reductions in heart failure 
hospitalizations mediated by their positive hemodynamic effects, while CV benefits for GLP-
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1RAs are primarily as a result of their effect on altering the progression of atherosclerosis, which 
is a relatively longer process than the hemodynamic effects that are seen with SGLT-2is. 
Consequently, a longer follow-up period, which was not attainable in our study, may have been 
needed to see these favorable effects in reducing ASCVD risk for GLP-1RAs, as well as for SGLT-
2is. Interestingly, both agents demonstrated significant reductions in unstable angina requiring 
hospitalizations, which was not observed in clinical trials. 
The lack of differences in CV outcomes between SGLT-2is and GLP-1As in our study 
provides some evidence that both drug classes, in general, may be equally effective in reducing 
CV risk in the broad T2D population. Currently, clinical guidelines only provide recommendations 
for these drug classes to be used specifically for T2D patients with established CVD. Moreover, 
only select agents within each drug class are currently recommended, which is limited to 
empagliflozin, canagliflozin, and liraglutide. However, it seems that a new paradigm shift in 
primary prevention of CVD may be underway. In March 2019, the American College of 
Cardiology (ACC) and the American Heart Association (AHA) released the 2019 Primary 
Prevention in Cardiovascular Disease guidelines, which outlines strategies focused on the primary 
prevention of CVD.51 Included in the guideline is a recommendation on primary prevention of 
CVD in adults with T2D as well as a treatment algorithm, recommending the initiation of either 
an SGLT-2i or a GLP-1RA as second-line or adjunct treatment to lifestyle modifications and 
metformin, although it was given a weak (level IIb) recommendation. Nonetheless, these new 
guidelines do not single out any preferred agent within each class, but rather provides the 
recommendation across their entirety. More evidence surrounding the broader use of these agents 
is expected to emerge in the upcoming years with investigations on the use of SGLT-2is in the 
absence of T2D, CVOT results that include a population of patients without CVD, as is the case 
with REWIND (dulaglutide) where only 31% reportedly had established CVD, as well as the first 




There were several limitations in this study. First, given the observational and retrospective 
nature of the study design, there is always a risk of residual unmeasured confounding that could 
not be entirely accounted for from the information available with the limited bandwidth of single-
system administrative claims and EHR data alone. Out of 9,477 unique patients in the study, only 
45.7% (4,328) had available HbA1c, which prevented the ability to use HbA1c as a covariate in 
our propensity score models. Multiple imputation and missing indicator methods were considered 
a possible solution52; however, it was unlikely the best approach without introducing significant 
bias within our results, given that over 50% of the study population had missing values. Second, 
we were unable to directly consider the duration of diabetes for each patient, which has been found 
to be positively correlated with an increased risk of CV outcomes.53 Nonetheless, we were able to 
incorporate other related measures as proxies for evaluating diabetes severity, such as the presence 
of micro- and macrovascular disease and the number of baseline antidiabetic agents. Third, our 
data source did not allow us to investigate CV death as a study endpoint of interest, which prevents 
the ability to compare our results to other studies that examined CV mortality. However, because 
we included other CV outcomes that were assessed in other studies, we were able to compare our 
results for individual CV endpoints. Finally, our results should be taken in the context of the 
population sample that was included, which was limited to an insured adult T2D population in 
Texas. Therefore, our results may not be generalizable outside of our institution or geographic 
coverage. However, despite these limitations, our results were generally consistent with results 
from other studies and provides useful insights that can be applied to similar institutions to help 
guide health-care decision making.  
4.3 CONCLUSIONS 
Both SGLT-2is and GLP-1RAs showed significant reductions in the composite CV 
outcome and unstable angina requiring hospitalization compared to other antidiabetic drug classes. 
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However, only SGLT-2is were associated with a lower risk of HF hospitalizations. This suggests 
that both SGLT-2is and GLP-1RAs are both equally effective at reducing CVD outcomes in 
patients with T2D compared to other antidiabetic agents. However, SGLT-2is may be more 
effective for heart failure-related events. Nevertheless, CV outcomes were similar between SGLT-
2is and GLP-1RAs when compared to each other. This study provides real-world evidence for 
patients, payers, and providers to consider the selection of these novel antidiabetic agents with 
demonstrated CV benefits over other agents regardless of CVD status. Future investigation is 
needed regarding whether heart failure benefit with SGLT-2is is similar between heart failure 
patients with reduced ejection fraction and preserved ejection fraction. In addition, investigation 
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Appendix A: Search Terms for Antidiabetic Drug Classes 
Drug Class Search Terms 
Sodium-glucose cotransporter-2 inhibitors 
  CANAGLIFLOZIN JARDIANCE 
  DAPAGLIFLOZIN QTERN 
  EMPAGLIFLOZIN SEGLUROMET 
  ERTUGLIFLOZIN STEGLATRO 
  FARXIGA STEGLUJAN 
  GLYXAMBI SYNJARDY 
  INVOKAMET XIGDUO 
  INVOKANA   
Glucagon-like peptide-1 receptor agonists 
  ADLYXIN OZEMPIC 
  ALBIGLUTIDE SEMAGLUTIDE 
  BYDUREON SOLIQUA 
  BYETTA TANZEUM 
  DULAGLUTIDE TRULICITY 
  EXENATIDE VICTOZA 
  LIRAGLUTIDE XULTOPHY 
  LIXISENATIDE   
Other antidiabetic medications 
Metformin ACTOPLUS JENTADUETO 
  AVANDAMET KAZANO 
  FORTAMET KOMBIGLYZE 
  GLUCOPHAGE METFORMIN 
  GLUCOPHAGE XR PRANDIMET 
  GLUCOVANCE SEGLUROMET 
  GLUMETZA SYNJARDY 
  INVOKAMET XIGDUO 
  JANUMET   
Dipeptidyl peptidase-4 inhibitors ALOGLIPTIN NESINA 
  GLYXAMBI ONGLYZA 
  JANUMET OSENI 
  JANUVIA QTERN 
  JENTADUETO SAXAGLIPTIN 
  JUVISYNC SITAGLIPTIN 
  KAZANO STEGLUJAN 
  KOMBIGLYZE TRADJENTA 
  LINAGLIPTIN   
 86 
 
Sulfonylureas AMARYL GLUCOTROL 
  CHLORPROPAMIDE GLYBURIDE 
  DIABETA GLYNASE 
  GLIMEPIRIDE TOLAZAMIDE 
  GLIPIZIDE TOLBUTAMIDE 
Thiazolidinediones ACTOPLUS AVANDIA 
  ACTOS PIOGLITAZONE 
  AVANDAMET ROSIGLITAZONE 
  AVANDARYL   
Alpha-glucosidase inhibitors ACARBOSE PRECOSE 
  MIGLITOL   
Meglinitides NATEGLINIDE REPAGLINIDE 
  PRANDIMET STARLIX 
  PRANDIN   
Insulin ADMELOG LANTUS 
  AFREZZA LEVEMIR 
  APIDRA NOVOLIN 
  BASAGLAR NOVOLOG 
  FIASP SOLIQUA 
  HUMALOG TOUJEO 
  HUMULIN TRESIBA 




Appendix B. Diagnosis Codes for Cardiovascular Outcomes 
Myocardial infarction definition: Hospital discharge/inpatient diagnosis of relevant codes 
Code Type Code Code Type Code Code Type Code 
ICD9 DIAGNOSIS 410 ICD9 DIAGNOSIS 410.61 ICD10 DIAGNOSIS I21.3 
ICD9 DIAGNOSIS 410 ICD9 DIAGNOSIS 410.7 ICD10 DIAGNOSIS I21.4 
ICD9 DIAGNOSIS 410 ICD9 DIAGNOSIS 410.7 ICD10 DIAGNOSIS I21.9 
ICD9 DIAGNOSIS 410.01 ICD9 DIAGNOSIS 410.71 ICD10 DIAGNOSIS I21.A 
ICD9 DIAGNOSIS 410.1 ICD9 DIAGNOSIS 410.8 ICD10 DIAGNOSIS I21.A1 
ICD9 DIAGNOSIS 410.1 ICD9 DIAGNOSIS 410.8 ICD10 DIAGNOSIS I21.A9 
ICD9 DIAGNOSIS 410.11 ICD9 DIAGNOSIS 410.81 ICD10 DIAGNOSIS I22 
ICD9 DIAGNOSIS 410.2 ICD9 DIAGNOSIS 410.9 ICD10 DIAGNOSIS I22.0 
ICD9 DIAGNOSIS 410.2 ICD9 DIAGNOSIS 410.9 ICD10 DIAGNOSIS I22.1 
ICD9 DIAGNOSIS 410.21 ICD9 DIAGNOSIS 410.91 ICD10 DIAGNOSIS I22.2 
ICD9 DIAGNOSIS 410.3 ICD10 DIAGNOSIS I21 ICD10 DIAGNOSIS I22.8 
ICD9 DIAGNOSIS 410.3 ICD10 DIAGNOSIS I21.0 ICD10 DIAGNOSIS I22.9 
ICD9 DIAGNOSIS 410.31 ICD10 DIAGNOSIS I21.01 ICD10 DIAGNOSIS I23.0 
ICD9 DIAGNOSIS 410.4 ICD10 DIAGNOSIS I21.02 ICD10 DIAGNOSIS I23.1 
ICD9 DIAGNOSIS 410.4 ICD10 DIAGNOSIS I21.09 ICD10 DIAGNOSIS I23.2 
ICD9 DIAGNOSIS 410.41 ICD10 DIAGNOSIS I21.1 ICD10 DIAGNOSIS I23.3 
ICD9 DIAGNOSIS 410.5 ICD10 DIAGNOSIS I21.11 ICD10 DIAGNOSIS I23.4 
ICD9 DIAGNOSIS 410.5 ICD10 DIAGNOSIS I21.19 ICD10 DIAGNOSIS I23.5 
ICD9 DIAGNOSIS 410.51 ICD10 DIAGNOSIS I21.2 ICD10 DIAGNOSIS I23.6 
ICD9 DIAGNOSIS 410.6 ICD10 DIAGNOSIS I21.21 ICD10 DIAGNOSIS I23.8 
ICD9 DIAGNOSIS 410.6 ICD10 DIAGNOSIS I21.29    
Unstable angina definition: Hospital discharge/inpatient diagnosis of relevant codes: 
Code Type Code Code Type Code Code Type Code 
ICD9 DIAGNOSIS 411 ICD10 DIAGNOSIS I24 ICD10 DIAGNOSIS I25.710 
ICD9 DIAGNOSIS 411 ICD10 DIAGNOSIS I24.0 ICD10 DIAGNOSIS I25.720 
ICD9 DIAGNOSIS 411.1 ICD10 DIAGNOSIS I24.1 ICD10 DIAGNOSIS I25.730 
ICD9 DIAGNOSIS 411.8 ICD10 DIAGNOSIS I24.8 ICD10 DIAGNOSIS I25.750 
ICD9 DIAGNOSIS 411.81 ICD10 DIAGNOSIS I24.9 ICD10 DIAGNOSIS I25.760 
ICD9 DIAGNOSIS 411.89 ICD10 DIAGNOSIS I25.110 ICD10 DIAGNOSIS I25.790 
ICD10 DIAGNOSIS I20.0 ICD10 DIAGNOSIS I25.700    
Ischemic stroke definition: Hospital discharge/inpatient diagnosis of relevant codes 
Code Type Code Code Type Code Code Type Code 
ICD9 DIAGNOSIS 433.01 ICD10 DIAGNOSIS I63.19 ICD10 DIAGNOSIS I63.421 
ICD9 DIAGNOSIS 433.11 ICD10 DIAGNOSIS I63.2 ICD10 DIAGNOSIS I63.422 
ICD9 DIAGNOSIS 433.21 ICD10 DIAGNOSIS I63.20 ICD10 DIAGNOSIS I63.423 
ICD9 DIAGNOSIS 433.31 ICD10 DIAGNOSIS I63.21 ICD10 DIAGNOSIS I63.429 
ICD9 DIAGNOSIS 433.81 ICD10 DIAGNOSIS I63.211 ICD10 DIAGNOSIS I63.43 
 88 
 
ICD9 DIAGNOSIS 433.91 ICD10 DIAGNOSIS I63.212 ICD10 DIAGNOSIS I63.431 
ICD9 DIAGNOSIS 434.01 ICD10 DIAGNOSIS I63.213 ICD10 DIAGNOSIS I63.432 
ICD9 DIAGNOSIS 434.11 ICD10 DIAGNOSIS I63.219 ICD10 DIAGNOSIS I63.433 
ICD9 DIAGNOSIS 434.91 ICD10 DIAGNOSIS I63.22 ICD10 DIAGNOSIS I63.439 
ICD9 DIAGNOSIS 436 ICD10 DIAGNOSIS I63.23 ICD10 DIAGNOSIS I63.44 
ICD10 DIAGNOSIS G43.6 ICD10 DIAGNOSIS I63.231 ICD10 DIAGNOSIS I63.441 
ICD10 DIAGNOSIS G43.601 ICD10 DIAGNOSIS I63.232 ICD10 DIAGNOSIS I63.442 
ICD10 DIAGNOSIS G43.609 ICD10 DIAGNOSIS I63.233 ICD10 DIAGNOSIS I63.443 
ICD10 DIAGNOSIS G43.611 ICD10 DIAGNOSIS I63.239 ICD10 DIAGNOSIS I63.449 
ICD10 DIAGNOSIS G43.619 ICD10 DIAGNOSIS I63.29 ICD10 DIAGNOSIS I63.49 
ICD10 DIAGNOSIS G46.3 ICD10 DIAGNOSIS I63.3 ICD10 DIAGNOSIS I63.5 
ICD10 DIAGNOSIS G46.4 ICD10 DIAGNOSIS I63.30 ICD10 DIAGNOSIS I63.50 
ICD10 DIAGNOSIS G95.11 ICD10 DIAGNOSIS I63.31 ICD10 DIAGNOSIS I63.51 
ICD10 DIAGNOSIS I63 ICD10 DIAGNOSIS I63.311 ICD10 DIAGNOSIS I63.511 
ICD10 DIAGNOSIS I63.0 ICD10 DIAGNOSIS I63.312 ICD10 DIAGNOSIS I63.512 
ICD10 DIAGNOSIS I63.00 ICD10 DIAGNOSIS I63.313 ICD10 DIAGNOSIS I63.513 
ICD10 DIAGNOSIS I63.01 ICD10 DIAGNOSIS I63.319 ICD10 DIAGNOSIS I63.519 
ICD10 DIAGNOSIS I63.011 ICD10 DIAGNOSIS I63.32 ICD10 DIAGNOSIS I63.52 
ICD10 DIAGNOSIS I63.012 ICD10 DIAGNOSIS I63.321 ICD10 DIAGNOSIS I63.521 
ICD10 DIAGNOSIS I63.013 ICD10 DIAGNOSIS I63.322 ICD10 DIAGNOSIS I63.522 
ICD10 DIAGNOSIS I63.019 ICD10 DIAGNOSIS I63.323 ICD10 DIAGNOSIS I63.523 
ICD10 DIAGNOSIS I63.02 ICD10 DIAGNOSIS I63.329 ICD10 DIAGNOSIS I63.529 
ICD10 DIAGNOSIS I63.03 ICD10 DIAGNOSIS I63.33 ICD10 DIAGNOSIS I63.53 
ICD10 DIAGNOSIS I63.031 ICD10 DIAGNOSIS I63.331 ICD10 DIAGNOSIS I63.531 
ICD10 DIAGNOSIS I63.032 ICD10 DIAGNOSIS I63.332 ICD10 DIAGNOSIS I63.532 
ICD10 DIAGNOSIS I63.033 ICD10 DIAGNOSIS I63.333 ICD10 DIAGNOSIS I63.533 
ICD10 DIAGNOSIS I63.039 ICD10 DIAGNOSIS I63.339 ICD10 DIAGNOSIS I63.539 
ICD10 DIAGNOSIS I63.09 ICD10 DIAGNOSIS I63.34 ICD10 DIAGNOSIS I63.54 
ICD10 DIAGNOSIS I63.1 ICD10 DIAGNOSIS I63.341 ICD10 DIAGNOSIS I63.541 
ICD10 DIAGNOSIS I63.10 ICD10 DIAGNOSIS I63.342 ICD10 DIAGNOSIS I63.542 
ICD10 DIAGNOSIS I63.11 ICD10 DIAGNOSIS I63.343 ICD10 DIAGNOSIS I63.543 
ICD10 DIAGNOSIS I63.111 ICD10 DIAGNOSIS I63.349 ICD10 DIAGNOSIS I63.549 
ICD10 DIAGNOSIS I63.112 ICD10 DIAGNOSIS I63.39 ICD10 DIAGNOSIS I63.59 
ICD10 DIAGNOSIS I63.113 ICD10 DIAGNOSIS I63.4 ICD10 DIAGNOSIS I63.6 
ICD10 DIAGNOSIS I63.119 ICD10 DIAGNOSIS I63.40 ICD10 DIAGNOSIS I63.8 
ICD10 DIAGNOSIS I63.12 ICD10 DIAGNOSIS I63.41 ICD10 DIAGNOSIS I63.9 
ICD10 DIAGNOSIS I63.13 ICD10 DIAGNOSIS I63.411 ICD10 DIAGNOSIS I97.810 
ICD10 DIAGNOSIS I63.131 ICD10 DIAGNOSIS I63.412 ICD10 DIAGNOSIS I97.811 
ICD10 DIAGNOSIS I63.132 ICD10 DIAGNOSIS I63.413 ICD10 DIAGNOSIS I97.82 
ICD10 DIAGNOSIS I63.133 ICD10 DIAGNOSIS I63.419 ICD10 DIAGNOSIS I97.820 
ICD10 DIAGNOSIS I63.139 ICD10 DIAGNOSIS I63.42 ICD10 DIAGNOSIS I97.821 
ICD9 DIAGNOSIS 435 ICD10 DIAGNOSIS G45.0 ICD10 DIAGNOSIS I67.84 
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ICD9 DIAGNOSIS 435 ICD10 DIAGNOSIS G45.1 ICD10 DIAGNOSIS I67.841 
ICD9 DIAGNOSIS 435.1 ICD10 DIAGNOSIS G45.2 ICD10 DIAGNOSIS I67.848 
ICD9 DIAGNOSIS 435.2 ICD10 DIAGNOSIS G45.8 ICD10 DIAGNOSIS M47.0 
ICD9 DIAGNOSIS 435.3 ICD10 DIAGNOSIS G45.9 ICD10 DIAGNOSIS M47.02 
ICD9 DIAGNOSIS 435.8 ICD10 DIAGNOSIS G46.0 ICD10 DIAGNOSIS M47.021 
ICD9 DIAGNOSIS 435.9 ICD10 DIAGNOSIS G46.1 ICD10 DIAGNOSIS M47.022 
ICD10 DIAGNOSIS G45 ICD10 DIAGNOSIS G46.2 ICD10 DIAGNOSIS M47.029 
Heart failure definition: Hospital discharge/inpatient diagnosis of relevant codes 
Code Type Code Code Type Code Code Type Code 
ICD9 DIAGNOSIS 398.91 ICD9 DIAGNOSIS 428.32 ICD10 DIAGNOSIS I50.31 
ICD9 DIAGNOSIS 402.01 ICD9 DIAGNOSIS 428.33 ICD10 DIAGNOSIS I50.32 
ICD9 DIAGNOSIS 402.11 ICD9 DIAGNOSIS 428.4 ICD10 DIAGNOSIS I50.33 
ICD9 DIAGNOSIS 402.91 ICD9 DIAGNOSIS 428.4 ICD10 DIAGNOSIS I50.4 
ICD9 DIAGNOSIS 404.01 ICD9 DIAGNOSIS 428.41 ICD10 DIAGNOSIS I50.40 
ICD9 DIAGNOSIS 404.03 ICD9 DIAGNOSIS 428.42 ICD10 DIAGNOSIS I50.41 
ICD9 DIAGNOSIS 404.11 ICD9 DIAGNOSIS 428.43 ICD10 DIAGNOSIS I50.42 
ICD9 DIAGNOSIS 404.13 ICD9 DIAGNOSIS 428.9 ICD10 DIAGNOSIS I50.43 
ICD9 DIAGNOSIS 404.91 ICD10 DIAGNOSIS I09.81 ICD10 DIAGNOSIS I50.8 
ICD9 DIAGNOSIS 404.93 ICD10 DIAGNOSIS I11.0 ICD10 DIAGNOSIS I50.81 
ICD9 DIAGNOSIS 428 ICD10 DIAGNOSIS I13.0 ICD10 DIAGNOSIS I50.810 
ICD9 DIAGNOSIS 428 ICD10 DIAGNOSIS I13.2 ICD10 DIAGNOSIS I50.811 
ICD9 DIAGNOSIS 428.1 ICD10 DIAGNOSIS I50 ICD10 DIAGNOSIS I50.812 
ICD9 DIAGNOSIS 428.2 ICD10 DIAGNOSIS I150.1 ICD10 DIAGNOSIS I50.813 
ICD9 DIAGNOSIS 428.2 ICD10 DIAGNOSIS I50.2 ICD10 DIAGNOSIS I50.814 
ICD9 DIAGNOSIS 428.21 ICD10 DIAGNOSIS I50.20 ICD10 DIAGNOSIS I50.82 
ICD9 DIAGNOSIS 428.22 ICD10 DIAGNOSIS I50.21 ICD10 DIAGNOSIS I50.83 
ICD9 DIAGNOSIS 428.23 ICD10 DIAGNOSIS I50.22 ICD10 DIAGNOSIS I50.84 
ICD9 DIAGNOSIS 428.3 ICD10 DIAGNOSIS I50.23 ICD10 DIAGNOSIS I50.89 
ICD9 DIAGNOSIS 428.3 ICD10 DIAGNOSIS I50.3 ICD10 DIAGNOSIS I50.9 
ICD9 DIAGNOSIS 428.31 ICD10 DIAGNOSIS I50.30 ICD10 DIAGNOSIS I97.13 
Coronary Revascularization definition 
Code Type Code Code Type Code Code Type Code 
ICD9 PROCEDURE 36.1 ICD10 PROCEDURE 02110KF ICD10 PROCEDURE 02124K8 
ICD9 PROCEDURE 36.11 ICD10 PROCEDURE 02110KW ICD10 PROCEDURE 02124K9 
ICD9 PROCEDURE 36.12 ICD10 PROCEDURE 02110Z3 ICD10 PROCEDURE 02124KC 
ICD9 PROCEDURE 36.13 ICD10 PROCEDURE 02110Z8 ICD10 PROCEDURE 02124KF 
ICD9 PROCEDURE 36.14 ICD10 PROCEDURE 02110Z9 ICD10 PROCEDURE 02124KW 
ICD9 PROCEDURE 36.15 ICD10 PROCEDURE 02110ZC ICD10 PROCEDURE 02124Z3 
ICD9 PROCEDURE 36.16 ICD10 PROCEDURE 02110ZF ICD10 PROCEDURE 02124Z8 
ICD9 PROCEDURE 36.17 ICD10 PROCEDURE 211344 ICD10 PROCEDURE 02124Z9 
ICD9 PROCEDURE 36.19 ICD10 PROCEDURE 02113D4 ICD10 PROCEDURE 02124ZC 
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ICD10 PROCEDURE 210098 ICD10 PROCEDURE 211444 ICD10 PROCEDURE 02124ZF 
ICD10 PROCEDURE 210099 ICD10 PROCEDURE 211493 ICD10 PROCEDURE 213 
ICD10 PROCEDURE 021009C ICD10 PROCEDURE 211498 ICD10 PROCEDURE 213093 
ICD10 PROCEDURE 021009F ICD10 PROCEDURE 211499 ICD10 PROCEDURE 213098 
ICD10 PROCEDURE 021009W ICD10 PROCEDURE 021149C ICD10 PROCEDURE 213099 
ICD10 PROCEDURE 02100A3 ICD10 PROCEDURE 021149F ICD10 PROCEDURE 021309C 
ICD10 PROCEDURE 02100A8 ICD10 PROCEDURE 021149W ICD10 PROCEDURE 021309F 
ICD10 PROCEDURE 02100A9 ICD10 PROCEDURE 02114A3 ICD10 PROCEDURE 021309W 
ICD10 PROCEDURE 02100AC ICD10 PROCEDURE 02114A8 ICD10 PROCEDURE 02130A3 
ICD10 PROCEDURE 02100AF ICD10 PROCEDURE 02114A9 ICD10 PROCEDURE 02130A8 
ICD10 PROCEDURE 02100AW ICD10 PROCEDURE 02114AC ICD10 PROCEDURE 02130A9 
ICD10 PROCEDURE 02100J3 ICD10 PROCEDURE 02114AF ICD10 PROCEDURE 02130AC 
ICD10 PROCEDURE 02100J8 ICD10 PROCEDURE 02114AW ICD10 PROCEDURE 02130AF 
ICD10 PROCEDURE 02100J9 ICD10 PROCEDURE 02114D4 ICD10 PROCEDURE 02130AW 
ICD10 PROCEDURE 02100JC ICD10 PROCEDURE 02114J3 ICD10 PROCEDURE 02130J3 
ICD10 PROCEDURE 02100JF ICD10 PROCEDURE 02114J8 ICD10 PROCEDURE 02130J8 
ICD10 PROCEDURE 02100JW ICD10 PROCEDURE 02114J9 ICD10 PROCEDURE 02130J9 
ICD10 PROCEDURE 02100K3 ICD10 PROCEDURE 02114JC ICD10 PROCEDURE 02130JC 
ICD10 PROCEDURE 02100K8 ICD10 PROCEDURE 02114JF ICD10 PROCEDURE 02130JF 
ICD10 PROCEDURE 02100K9 ICD10 PROCEDURE 02114JW ICD10 PROCEDURE 02130JW 
ICD10 PROCEDURE 02100KC ICD10 PROCEDURE 02114K3 ICD10 PROCEDURE 02130K3 
ICD10 PROCEDURE 02100KF ICD10 PROCEDURE 02114K8 ICD10 PROCEDURE 02130K8 
ICD10 PROCEDURE 02100KW ICD10 PROCEDURE 02114K9 ICD10 PROCEDURE 02130K9 
ICD10 PROCEDURE 02100Z3 ICD10 PROCEDURE 02114KC ICD10 PROCEDURE 02130KC 
ICD10 PROCEDURE 02100Z8 ICD10 PROCEDURE 02114KF ICD10 PROCEDURE 02130KF 
ICD10 PROCEDURE 02100Z9 ICD10 PROCEDURE 02114KW ICD10 PROCEDURE 02130KW 
ICD10 PROCEDURE 02100ZC ICD10 PROCEDURE 02114Z3 ICD10 PROCEDURE 02130Z3 
ICD10 PROCEDURE 02100ZF ICD10 PROCEDURE 02114Z8 ICD10 PROCEDURE 02130Z8 
ICD10 PROCEDURE 210344 ICD10 PROCEDURE 02114Z9 ICD10 PROCEDURE 02130Z9 
ICD10 PROCEDURE 02103D4 ICD10 PROCEDURE 02114ZC ICD10 PROCEDURE 02130ZC 
ICD10 PROCEDURE 210444 ICD10 PROCEDURE 02114ZF ICD10 PROCEDURE 02130ZF 
ICD10 PROCEDURE 210493 ICD10 PROCEDURE 212 ICD10 PROCEDURE 213344 
ICD10 PROCEDURE 210498 ICD10 PROCEDURE 212093 ICD10 PROCEDURE 02133D4 
ICD10 PROCEDURE 210499 ICD10 PROCEDURE 212098 ICD10 PROCEDURE 213444 
ICD10 PROCEDURE 021049C ICD10 PROCEDURE 212099 ICD10 PROCEDURE 213493 
ICD10 PROCEDURE 021049F ICD10 PROCEDURE 021209C ICD10 PROCEDURE 213498 
ICD10 PROCEDURE 021049W ICD10 PROCEDURE 021209F ICD10 PROCEDURE 213499 
ICD10 PROCEDURE 02104A3 ICD10 PROCEDURE 021209W ICD10 PROCEDURE 021349C 
ICD10 PROCEDURE 02104A8 ICD10 PROCEDURE 02120A3 ICD10 PROCEDURE 021349F 
ICD10 PROCEDURE 02104A9 ICD10 PROCEDURE 02120A8 ICD10 PROCEDURE 021349W 
ICD10 PROCEDURE 02104AC ICD10 PROCEDURE 02120A9 ICD10 PROCEDURE 02134A3 
ICD10 PROCEDURE 02104AF ICD10 PROCEDURE 02120AC ICD10 PROCEDURE 02134A8 
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ICD10 PROCEDURE 02104AW ICD10 PROCEDURE 02120AF ICD10 PROCEDURE 02134A9 
ICD10 PROCEDURE 02104D4 ICD10 PROCEDURE 02120AW ICD10 PROCEDURE 02134AC 
ICD10 PROCEDURE 02104J3 ICD10 PROCEDURE 02120J3 ICD10 PROCEDURE 02134AF 
ICD10 PROCEDURE 02104J8 ICD10 PROCEDURE 02120J8 ICD10 PROCEDURE 02134AW 
ICD10 PROCEDURE 02104J9 ICD10 PROCEDURE 02120J9 ICD10 PROCEDURE 02134D4 
ICD10 PROCEDURE 02104JC ICD10 PROCEDURE 02120JC ICD10 PROCEDURE 02134J3 
ICD10 PROCEDURE 02104JF ICD10 PROCEDURE 02120JF ICD10 PROCEDURE 02134J8 
ICD10 PROCEDURE 02104JW ICD10 PROCEDURE 02120JW ICD10 PROCEDURE 02134J9 
ICD10 PROCEDURE 02104K3 ICD10 PROCEDURE 02120K3 ICD10 PROCEDURE 02134JC 
ICD10 PROCEDURE 02104K8 ICD10 PROCEDURE 02120K8 ICD10 PROCEDURE 02134JF 
ICD10 PROCEDURE 02104K9 ICD10 PROCEDURE 02120K9 ICD10 PROCEDURE 02134JW 
ICD10 PROCEDURE 02104KC ICD10 PROCEDURE 02120KC ICD10 PROCEDURE 02134K3 
ICD10 PROCEDURE 02104KF ICD10 PROCEDURE 02120KF ICD10 PROCEDURE 02134K8 
ICD10 PROCEDURE 02104KW ICD10 PROCEDURE 02120KW ICD10 PROCEDURE 02134K9 
ICD10 PROCEDURE 02104Z3 ICD10 PROCEDURE 02120Z3 ICD10 PROCEDURE 02134KC 
ICD10 PROCEDURE 02104Z8 ICD10 PROCEDURE 02120Z8 ICD10 PROCEDURE 02134KF 
ICD10 PROCEDURE 02104Z9 ICD10 PROCEDURE 02120Z9 ICD10 PROCEDURE 02134KW 
ICD10 PROCEDURE 02104ZC ICD10 PROCEDURE 02120ZC ICD10 PROCEDURE 02134Z3 
ICD10 PROCEDURE 02104ZF ICD10 PROCEDURE 02120ZF ICD10 PROCEDURE 02134Z8 
ICD10 PROCEDURE 211 ICD10 PROCEDURE 212344 ICD10 PROCEDURE 02134Z9 
ICD10 PROCEDURE 211093 ICD10 PROCEDURE 02123D4 ICD10 PROCEDURE 02134ZC 
ICD10 PROCEDURE 211098 ICD10 PROCEDURE 212444 ICD10 PROCEDURE 02134ZF 
ICD10 PROCEDURE 211099 ICD10 PROCEDURE 212493 CPT4 33510 
ICD10 PROCEDURE 021109C ICD10 PROCEDURE 212498 CPT4 33511 
ICD10 PROCEDURE 021109F ICD10 PROCEDURE 212499 CPT4 33512 
ICD10 PROCEDURE 021109W ICD10 PROCEDURE 021249C CPT4 33513 
ICD10 PROCEDURE 02110A3 ICD10 PROCEDURE 021249F CPT4 33514 
ICD10 PROCEDURE 02110A8 ICD10 PROCEDURE 021249W CPT4 33516 
ICD10 PROCEDURE 02110A9 ICD10 PROCEDURE 02124A3 CPT4 33517 
ICD10 PROCEDURE 02110AC ICD10 PROCEDURE 02124A8 CPT4 33518 
ICD10 PROCEDURE 02110AF ICD10 PROCEDURE 02124A9 CPT4 33519 
ICD10 PROCEDURE 02110AW ICD10 PROCEDURE 02124AC CPT4 33521 
ICD10 PROCEDURE 02110J3 ICD10 PROCEDURE 02124AF CPT4 33522 
ICD10 PROCEDURE 02110J8 ICD10 PROCEDURE 02124AW CPT4 33523 
ICD10 PROCEDURE 02110J9 ICD10 PROCEDURE 02124D4 CPT4 33530 
ICD10 PROCEDURE 02110JC ICD10 PROCEDURE 02124J3 CPT4 33533 
ICD10 PROCEDURE 02110JF ICD10 PROCEDURE 02124J8 CPT4 33534 
ICD10 PROCEDURE 02110JW ICD10 PROCEDURE 02124J9 CPT4 33535 
ICD10 PROCEDURE 02110K3 ICD10 PROCEDURE 02124JC CPT4 33536 
ICD10 PROCEDURE 02110K8 ICD10 PROCEDURE 02124JF CPT4 33572 
ICD10 PROCEDURE 02110K9 ICD10 PROCEDURE 02124JW CPT4 4110F 
ICD10 PROCEDURE 02110KC ICD10 PROCEDURE 02124K3    
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ICD9 PROCEDURE 0.66 ICD10 PROCEDURE 02713ZZ ICD10 PROCEDURE 02733ZZ 
ICD9 PROCEDURE 36 ICD10 PROCEDURE 271446 ICD10 PROCEDURE 273446 
ICD9 PROCEDURE 36 ICD10 PROCEDURE 027144Z ICD10 PROCEDURE 027344Z 
ICD9 PROCEDURE 36.01 ICD10 PROCEDURE 02714D6 ICD10 PROCEDURE 02734D6 
ICD9 PROCEDURE 36.02 ICD10 PROCEDURE 02714DZ ICD10 PROCEDURE 02734DZ 
ICD9 PROCEDURE 36.05 ICD10 PROCEDURE 02714T6 ICD10 PROCEDURE 02734T6 
ICD9 PROCEDURE 36.06 ICD10 PROCEDURE 02714TZ ICD10 PROCEDURE 02734TZ 
ICD9 PROCEDURE 36.07 ICD10 PROCEDURE 02714Z6 ICD10 PROCEDURE 02734Z6 
ICD9 PROCEDURE 36.09 ICD10 PROCEDURE 02714ZZ ICD10 PROCEDURE 02734ZZ 
ICD10 PROCEDURE 270 ICD10 PROCEDURE 272 ICD10 PROCEDURE 02C00ZZ 
ICD10 PROCEDURE 270046 ICD10 PROCEDURE 272046 ICD10 PROCEDURE 02C03ZZ 
ICD10 PROCEDURE 027004Z ICD10 PROCEDURE 027204Z ICD10 PROCEDURE 02C04ZZ 
ICD10 PROCEDURE 02700D6 ICD10 PROCEDURE 02720D6 ICD10 PROCEDURE 02C10ZZ 
ICD10 PROCEDURE 02700DZ ICD10 PROCEDURE 02720DZ ICD10 PROCEDURE 02C13ZZ 
ICD10 PROCEDURE 02700T6 ICD10 PROCEDURE 02720T6 ICD10 PROCEDURE 02C14ZZ 
ICD10 PROCEDURE 02700TZ ICD10 PROCEDURE 02720TZ ICD10 PROCEDURE 02C20ZZ 
ICD10 PROCEDURE 02700Z6 ICD10 PROCEDURE 02720Z6 ICD10 PROCEDURE 02C23ZZ 
ICD10 PROCEDURE 02700ZZ ICD10 PROCEDURE 02720ZZ ICD10 PROCEDURE 02C24ZZ 
ICD10 PROCEDURE 270346 ICD10 PROCEDURE 272346 ICD10 PROCEDURE 02C30ZZ 
ICD10 PROCEDURE 027034Z ICD10 PROCEDURE 027234Z ICD10 PROCEDURE 02C33ZZ 
ICD10 PROCEDURE 02703D6 ICD10 PROCEDURE 02723D6 ICD10 PROCEDURE 02C34ZZ 
ICD10 PROCEDURE 02703DZ ICD10 PROCEDURE 02723DZ ICD10 PROCEDURE 02Q03ZZ 
ICD10 PROCEDURE 02703T6 ICD10 PROCEDURE 02723T6 ICD10 PROCEDURE 02Q04ZZ 
ICD10 PROCEDURE 02703TZ ICD10 PROCEDURE 02723TZ ICD10 PROCEDURE 02Q13ZZ 
ICD10 PROCEDURE 02703Z6 ICD10 PROCEDURE 02723Z6 ICD10 PROCEDURE 02Q14ZZ 
ICD10 PROCEDURE 02703ZZ ICD10 PROCEDURE 02723ZZ ICD10 PROCEDURE 02Q23ZZ 
ICD10 PROCEDURE 270446 ICD10 PROCEDURE 272446 ICD10 PROCEDURE 02Q24ZZ 
ICD10 PROCEDURE 027044Z ICD10 PROCEDURE 027244Z ICD10 PROCEDURE 02Q33ZZ 
ICD10 PROCEDURE 02704D6 ICD10 PROCEDURE 02724D6 ICD10 PROCEDURE 02Q34ZZ 
ICD10 PROCEDURE 02704DZ ICD10 PROCEDURE 02724DZ ICD10 PROCEDURE X2C0361 
ICD10 PROCEDURE 02704T6 ICD10 PROCEDURE 02724T6 ICD10 PROCEDURE X2C1361 
ICD10 PROCEDURE 02704TZ ICD10 PROCEDURE 02724TZ ICD10 PROCEDURE X2C2361 
ICD10 PROCEDURE 02704Z6 ICD10 PROCEDURE 02724Z6 ICD10 PROCEDURE X2C3361 
ICD10 PROCEDURE 02704ZZ ICD10 PROCEDURE 02724ZZ CPT4 92920 
ICD10 PROCEDURE 271 ICD10 PROCEDURE 273 CPT4 92928 
ICD10 PROCEDURE 271046 ICD10 PROCEDURE 273046 CPT4 92929 
ICD10 PROCEDURE 027104Z ICD10 PROCEDURE 027304Z CPT4 92933 
ICD10 PROCEDURE 02710D6 ICD10 PROCEDURE 02730D6 CPT4 92934 
ICD10 PROCEDURE 02710DZ ICD10 PROCEDURE 02730DZ CPT4 92937 
ICD10 PROCEDURE 02710T6 ICD10 PROCEDURE 02730T6 CPT4 92938 
ICD10 PROCEDURE 02710TZ ICD10 PROCEDURE 02730TZ CPT4 92941 
ICD10 PROCEDURE 02710Z6 ICD10 PROCEDURE 02730Z6 CPT4 92943 
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ICD10 PROCEDURE 02710ZZ ICD10 PROCEDURE 02730ZZ CPT4 92944 
ICD10 PROCEDURE 271346 ICD10 PROCEDURE 273346 CPT4 92973 
ICD10 PROCEDURE 027134Z ICD10 PROCEDURE 027334Z CPT4 92980 
ICD10 PROCEDURE 02713D6 ICD10 PROCEDURE 02733D6 CPT4 92981 
ICD10 PROCEDURE 02713DZ ICD10 PROCEDURE 02733DZ CPT4 92982 
ICD10 PROCEDURE 02713T6 ICD10 PROCEDURE 02733T6 CPT4 92984 
ICD10 PROCEDURE 02713TZ ICD10 PROCEDURE 02733TZ CPT4 92995 
ICD10 PROCEDURE 02713Z6 ICD10 PROCEDURE 02733Z6 CPT4 92996 
 
